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ABSTRACT
Lipid based systems and topical ocular inserts of various drugs were developed for the
intervention/treatment of posterior segment ocular complications. Indomethacin (IN) was
developed into solid lipid nanoparticles (SLNs) and Nanostructured lipid carriers (NLCs). Effect
of surface functionalization using chitosan (CS) on lipid nanocarriers was tested to evaluate
corneal penetration. Surface modification of SLNs with CS increased ocular penetration of IN.
NLCs maintained significantly higher IN concentrations in all ocular tissues tested, compared to
the other formulations evaluated in vivo.
Effect of surface poly (ethylene) glycol (PEG) functionalization of the NLCs on ocular
disposition was studied using Ciprofloxacin (CIP) as a model drug. Transcorneal penetration of
CIP from NLCs was optimum with PEG molecular weight in between 2K to 10K. In vivo ocular
tissue CIP concentrations attained from the various formulations was consistent with the in vitro
data obtained.
Feasibility of melt-cast, topical, ocular inserts for delivery of drugs, with different
physicochemical properties, to the posterior segment of the eye was studied. The model drugs
tested include indomethacin (IN), ciprofloxacin hydrochloride (CIP) and prednisolone sodium
phosphate (PSP). Transmembrane flux of IN, PSP and CIP were enhanced by ~3.5-folds, ~3.6folds and ~2.9-folds, respectively, from the polymeric inserts when compared to the control
formulations, post 3 h. Moreover, ocular inserts generated significantly higher drug levels in all
the ocular tissues, including the retina-choroid, when compared to their control formulations.
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Cationic lipid nanoparticles of Natamycin (NT) were also evaluated. NT SLNs were
compared with NT marketed formulation – 5% w/v ophthalmic suspension - in terms of
transcorneal permeation and in vivo ocular tissue distribution. Compared to Natacyn® control,
transcorneal permeability of NT was enhanced ~ 3-folds with the CLBN formulation. In vivo
studies demonstrated that CLBN, at a 50-fold lower dose, was as effective as the control
formulation in terms of NT delivery to the retinal tissues.
Resveratrol (RES), a multi-faceted candidate was formulated into SLNs. Transcorneal flux
of RES was increased ~ 1.5-folds with the SLN formulation, when compared to control
formulation. The results from the all the above studies demonstrated that lipid based systems and
melt-cast topical ocular inserts serve as viable platforms in the niche of ocular delivery.
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CHAPTER 1
INTRODUCTION
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1.1. Introduction
The eye is an extremely complex, secluded, and sensitive organ of the human body. Owing
to its unique anatomical, physiological, metabolic, dynamic and efflux barrier functionalities,
delivery of drugs / development of novel therapies targeting the posterior segment ocular tissues
(retina

&

vitreous

humor)

remains

a

significant

challenge.

The

human

Figure 1.1: Ocular anatomy showing different barriers
ocular structure and the penetration pathways involved in topical delivery are shown in figure 1.1.
The anterior and posterior segment of eye is demarcated by the transparent crystalline lens. Cornea,
iris-ciliary (IC), lens, aqueous humor (AH), trabecular meshwork and Schlemm’s canal constitute
anterior segment. The anterior segment occupies approximately one-third portion of the eye. The
posterior segment consists of sclera, choroid, retina, vitreous humor and optic nerve (1).
1.1.1. Ocular anatomy and physiology
In humans, tear fluid often serves to clean and lubricate the eyes in response to irritation.
Lacrimal gland located at the upper lateral region of each orbit secretes the tear fluid which
continuously bathes the eye surface. Tear fluid forms tear film or pre-corneal film which consists
2

of three layers. The outermost lipid layer retards evaporation of water. The middle aqueous layer
which contains mainly water and small amounts of proteins. The innermost layer consists of mucin
and mainly water (95%). Mucins are typically large glycoproteins with molecular weight between
0.5 to 20 MDa. Following ocular instillation, topical eye drops will be diluted with the tear fluid
and get dispersed over the ocular surface with peak drug concentrations usually attained after 20
to 30 minutes. Eye drops are eliminated from the precorneal area within 90 seconds and undergo
systemic absorption. It is reported that precorneal half-life of topically applied drugs is between 13 min (2-4).
The cornea is major and primary structural component of the eye. The cornea is continuous
with white sclera and semi-transparent conjunctival tissue. The cornea is divided into three major
functional layers namely epithelium, stroma and endothelium. The corneal epithelium is lipophilic
and consists of three to six layers of tightly adherent cells which contribute to about 90% of the
barrier towards hydrophilic drugs. The stroma is hydrophilic constituting 90% of the corneal
thickness and acts as rate limiting barrier for lipophilic drugs. The endothelium is a one cell layer
thick lipophilic membrane with large intracellular junctions which does not restrict hydrophilic
drugs but may offer some resistance towards lipophilic drugs. The pore size of cornea is
approximately 1 nm (permeable for drugs with molecular weight (MW) less than about 700 Da)
while some studies indicate that some pores could be up to 5 nm in diameter. Pore density and
intercellular pore size in the cornea are much smaller than in the conjunctiva (5-7). The space
between the iris and the cornea is filled by fluid called aqueous humor, which maintains the
intraocular pressure in the eye. The amount of aqueous humor in the human and rabbit eye varies
between 200 and 300 µL. Reports indicated the entire fluid will be replaced in nearly 100 min (8).
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Lipophilic drugs are cleared by aqueous humor at a turnover rate of approximately 3 μL per minute
(9, 10).
The sclera is composed primarily of collagen fibers with mean thickness of 0.53 mm and
the mean total area of 16.3 cm2. The passive diffusion is primary route of drug penetration through
sclera. The permeability of sclera is largely dependent on the hydrodynamic radius of the
permeating drug molecule. Sclera is poorly vascularized and transport of large molecule may occur
through perivascular spaces or as diffusion between scleral fibrils (11, 12).
The conjunctival membrane is a vascularized tissue that covers ∼80% of the ocular surface
and secretes mucus. Hydrophilic drugs traverse through tight junctions of epithelium by
paracellular transport whereas lipophilic species penetrate through the transcellular route. The
conjunctiva–scleral route is alternative to major corneal absorption pathway for the topically
applied drugs to reach intraocular tissues. Propranolol, with logP of 3.21, is absorbed through
cornea and conjunctiva up to ten-fold greater than sotalol, a hydrophilic drug with a log P of −0.62.
However, efflux pumps (P-gp) localized on the apical side of conjunctiva restrict permeation of
lipophilic drugs. The conjunctiva is approximately 15 to 25 times more permeable than cornea
(13-15).
The blood ocular barriers comprise blood-aqueous barrier and the blood-retinal barrier
protecting the eye from xenobiotics. The blood-aqueous barrier is formed by the non-pigmented
epithelium of the ciliary body and the endothelium of the iris vessels. The blood-retinal barrier
consists of the retinal pigment epithelium and the endothelial membrane of the retinal vessels. The
two functional barriers restrict movement of drugs from oral or systemic administration into
intraocular tissues. However, the tight junctions of ciliary epithelium in rabbit eye are not effective
when compared to tight junctions of retina. Thus, blood-retinal barrier is superior to blood aqueous
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barrier in terms of limiting molecular diffusion (16). Lipophilic compounds are eliminated by
uveal blood flow at about 20 to 30 µL per minute (17-19). The choroid is a highly vascularized
layer between retina and sclera. It is composed of layers of blood vessels that nourish the back of
the eye of tissues. The choroidal vasculature serves as permeation barrier promoting clearance and
thus decreasing the bioavailability of drugs in the posterior segment from the topically applied
drugs. The vitreous humor is a clear aqueous gel consisting of mainly collagen and hyaluronan.
Long terms posterior complications require totally invasive intravitreal administration (20-22).
1.1.2. Posterior ocular segment complications
Diseases such as age-related macular degeneration (AMD), diabetic retinopathy (DR),
Glaucoma, uveitis, choroidal neovascularization (CNV), retinitis pigmentosa and retinoblastoma
account for most cases of irreversible blindness worldwide. However, statistical evidence suggests
that DR and AMD are the leading causes for irreversible blindness in the United States. DR is the
main cause of blindness in adults aged between 20 and 65 years, with incidence rates of 29% and
56% for proliferative and non-proliferative DR, respectively. Macular edema (ME) occurs in
approximately 10% of the diabetic population. AMD is the major cause of irreversible blindness
in adults older than 65 years. The prevalence of all forms of AMD in the 65 to 74 year age group
is 20%, and it is closer to 35% in older people (23).
Inflammation and oxidative stress are the underlying principal factors involved in the
etiology of most posterior segment ocular disorders. The relationship between hyperglycemia and
oxidative stress, which leads to the initiation and progression of several sight threatening ocular
diseases such as DR, AMD and cataract formation, is well established. The retina is highly
susceptible to oxidative damage due to the peroxidation of fatty acids present in its lipid bilayer.
Also, reports demonstrate that the total antioxidant capacity of the vitreous humor and aqueous
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humor is lowered in DR, accompanying generation of increased reactive oxygen species.
Numerous studies substantiate the prominent and critical role of inflammatory and angiogenic
pathways in the pathogenesis of DR. Thus, oxidative, inflammatory and angiogenic mechanisms
are involved in DR (24, 25). The multifactorial etiology of DR could be manifested in other
posterior diseases, hence there is increasing need for the development of multi-faceted candidates
and robust formulation platforms for the effective treatment of chorio-retinal complications.
DR can be broadly categorized into three stages; background DR, pre-proliferative DR and
proliferative DR (PDR). In background DR, hyperglycemia is considered to induce death in
endothelial cells of retinal blood vessels. Micro aneurysms and vascular leakage follow, and
blockage of retinal capillaries take place. In pre-proliferative DR, increasing retinal hypoxia and
multiple hemorrhages occurs in some areas. The angiogenic factors will be produced leading to
the proliferation of vessels, which is a typical feature of PDR. The newly formed blood vessels by
themselves do not lead to vision loss, but leakage of blood through their weak walls can result in
visual impairment and can ultimately lead to complete loss of sight (26-28).
Age-related macular degeneration (AMD) can be categorized into dry and wet AMD.
Progression of AMD is linked to the activation of inflammatory and immunological pathways.
Presence of excess ROS and decreased antioxidant capacity in the ocular tissues is also considered
to play a significant role in the initiation and progression of AMD. Oxidative stress induced
damage to the lens fibers is well documented in the case of cataracts. It is thought that these free
radicals accelerate and aggravate cataract development (29-32).
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1.1.3. Challenges encountered in topical drug delivery

Drug-Protein
Interaction

Tear reflexes, Turnover /
blinking of the eye
Drug Metabolism

Nasolacrimal outflow
and drainage

Non-Corneal Absorption

Precorneal / peri-ocular
loss

pH variability

Corneal route

Conjunctival / Scleral route
Barriers
Conjunctival and RC tissues
and metabolism

Barriers
- Cornea, Iris ciliary, lens, vitreous
humor tissues and their metabolism
Corneal Ultrastructure

Scleral, choroidal and retinal
vasculature and lymphatics
Protein Binding

Efflux mechanisms
Back-of-the eye

Figure 1.2: Schematic representation of ocular pathways and the underlying barriers encountered in topical
delivery to the BACK-OF-THE EYE.

Topical delivery of drugs to the posterior segment ocular tissues is an extremely
challenging task. Topical administration is the most favored route of administration, like other
localized modes, due to minimum non-specific systemic exposure, safety and patient compliance.
Conventional formulations such as eye drops, most favorably adopt the corneal route for delivery
of drugs. However, only 5-10% of the applied drug dose will be able to penetrate the inner ocular
tissues, following topical instillation, due to the pre-corneal factors. Moreover, efflux protein
pumps namely P-gp, multi-drug resistance protein (MRP) and breast cancer resistance protein
(BCRP) expression on the various ocular tissues play a critical role in lowering ocular
bioavailability of drug molecules. Drugs administered through alternative oral and
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systemic routes need to overcome the blood ocular barriers and may require higher doses, resulting
systemic toxicity (33).
1.2. Specific Objectives:
The goal of the present project is to develop topical lipid nanoparticulate and ocular
insert formulations with wide classes of drugs with anti-bacterial, anti-inflammatory, anti-fungal
properties. Model drugs tested include Indomethacin (IN), Ciprofloxacin (CIP), Prednisolone
sodium phosphate (PSP) and Natamycin. These drugs can be used especially in the treatment of
ocular inflammation/infections either alone or as a multi-drug combination therapy. The model
drugs chosen were formulated and evaluated in vitro / in vivo to demonstrate the feasibility of lipid
based systems and topical melt cast inserts for the back-of-the eye drug delivery.
1.3. Specific Aims
1. To evaluate the ocular penetration and distribution characteristics of IN loaded solid lipid
nanoparticles (IN-SLNs), IN loaded nanostructured lipid carriers (IN-NLCs) and IN loaded
chitosan coated SLNs (IN-CS-SLNs).
2. To demonstrate the effect of PEGylation in improving the penetration and sterilizationstabilization properties of CIP loaded NLCs.
3. To investigate the feasibility of melt cast ocular inserts to deliver drugs with wide range of
physico-chemical properties into the back-of-the eye.
4. To assess the ocular permeability and disposition of Natamycin from lipid nanoparticles in
comparison to marketed ophthalmic suspension.
5. To investigate the corneal penetration of Resveratrol from solid lipid nanoparticle
formulations.
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CHAPTER 2
TOPICAL OPHTHALMIC LIPID NANOPARTICLE FORMULATIONS (SLN, NLC)
OF INDOMETHACIN FOR DELIVERY TO THE POSTERIOR SEGMENT OCULAR
TISSUES
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2. Introduction
Indomethacin (IN), 2-{1-[(4-chlorophenyl) carbonyl] -5-methoxy-2-methyl-1H-indol-3yl} acetic acid, a topical non-steroidal anti-inflammatory drug (NSAID) is used in the treatment
of the ocular inflammatory disorders such as conjunctivitis, uveitis, cystoid macular edema, and
anterior segment inflammation, including post-operative pain following cataract surgery (34-36).
The compound elicits its anti-inflammatory action through the inhibition of COX-2 enzymes,
which are essential for prostaglandin biosynthesis, and thus possesses analgesic and anti-pyretic
properties (37). The potential effects of prostaglandins include elevation of intraocular pressure,
vasodilatation, disruption of blood ocular barriers, and leukocyte migration; hence, potent
inhibition of COX-2 enzymes may provide therapeutic effects (38). NSAIDs are employed in the
treatment of diabetic retinopathy and age-related macular degeneration (39). Formulating IN as a
topical ophthalmic solution is challenging due to its poor solubility and stability (40). Indosol,
which is an aqueous solution of IN complexed in TRIS-sodium salt (tromethamine), has been
widely used in ophthalmic research to treat inflammation of the anterior segment and the uvea
(41). Currently, topical ophthalmic formulations of IN are not marketed in the United States.
Indocollyre® (hydro-poly(ethylene glycol) (PEG) ophthalmic) 0.1% w/v eye drops, which are
commercially available in Europe, are associated with poor ocular bioavailability (42).
Approaches for improving the pre-corneal residence time and transcorneal permeability
characteristics could enhance intraocular bioavailability (1, 43). In recent years, colloidal
nanoparticulate systems have gained popularity as a promising ocular drug delivery platform (44).
Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) are colloidal
nanoparticulate systems designed and developed to deliver lipophilic drugs. These particulates are
composed of biocompatible and biodegradable materials and are in the nanometer size range. All
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excipients used in these formulations are generally regarded as safe, and process scale-up is
feasible. Several studies have demonstrated superior ocular bioavailability of therapeutic agents
from these colloidal nanoparticulate systems, possibly because of improved retention and
phagocytosis by epithelial cells. Furthermore, adsorption of polymers, such as chitosan, on the
surface of SLNs may further improve the retention of the nanoparticles on the epithelial surface
and increase cellular uptake of the nanoparticles (45, 46). Chitosan possesses favorable biological
characteristics, such as biodegradability, biocompatibility and mucoadhesive properties (47, 48).
The ability of chitosan and its derivatives in ophthalmic solutions to modulate characteristics of
the epithelial barrier through the transient opening of the tight junctions, which results in enhanced
transmembrane absorption, has been widely reported in the literature (49-51). In this study,
chitosan was used to modify the surface characteristics of SLNs (chitosan adsorbed onto the SLN
surface), and the ocular penetration of IN from the chitosan-coated SLNs was evaluated.
NLCs, however, appear to be a viable alternative to SLNs in terms of drug loading
efficiency and are prepared by incorporating liquid lipids within the solid lipid structure.
Depending on the ratio and concentration of the solid and liquid lipids, NLCs with different
structural matrices can be obtained (52, 53).
The objective of the current study was to develop and characterize various formulations,
such as SLNs, CS-SLNs and NLCs, and to evaluate the ocular delivery and disposition of IN from
these topically administered formulations.
2.1. Methods
2.1.1. Saturation solubility studies
Saturation solubility, as a function of pH, was studied by adding excess amount of IN to
screw-capped glass vials containing 200 mM phosphate buffer at different pH values, namely 5.5,
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6.0, 6.5, 7.0, and 7.4, and phosphate buffer with various solubilizers, such as HPβCD, RMβCD,
poloxamer 188, and Tween® 80. To achieve uniform mixing, samples were stirred at 100 rpm for
24 hrs at 25°C in a reciprocating water bath (Fisher Scientiﬁc). After 24 hrs, the samples were
centrifuged (AccuSpin 17R), and the supernatant was analyzed for drug content.
2.1.2. Chromatography system for in vitro sample analysis
Samples were analyzed for IN content using an high performance liquid chromatography
(HPLC) -UV method. A Phenomenex Luna® C18 4.6 mm x 250 mm column was used for the
analysis. The mobile phase used was methanol, water, and orthophosphoric acid (70:29.05:0.05).
The detection wavelength λmax for IN was 270 nm. The flow rate was set to 1 mL/min during the
analysis.
2.1.3. Formulations
IN-TSOL, IN-SOL and IN-CS-SOL formulations
IN-TSOL was prepared by dissolving 0.1% w/v IN in 1% w/v Tween® 80 solution, which
was used to investigate the release characteristics compared to the test formulations and to evaluate
barrier resistance. Additionally, IN-SOL was prepared by dissolving IN (0.1% w/v final
concentration) in an aqueous solution containing Tween®80 (1% w/v) and propylene glycol
(29.3% w/v). Sodium hydroxide (1N) was added in small increments to adjust the pH. IN-CS-SOL
was prepared by adding chitosan chloride (CS; 0.1% w/v final concentration) to IN-SOL. The pH
of the final formulations was maintained at 6.8 because Indocollyre®, a formulation marketed in
Europe, is at this pH.
IN-HPβCD and IN-CS- HPβCD solution formulations
IN-HPβCD formulation was prepared by dissolving IN (0.1% w/v) in 2.5% w/v HPβCD
solution prepared in isotonic phosphate-buffered saline (IPBS; pH 6.8). IN-CS-HPβCD was
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prepared by the addition of 0.1% w/v CS to the IN-HPβCD formulation. The final pH of the
formulations was adjusted to 6.8.
Indomethacin solid lipid nanoparticles (IN-SLN) and IN-SLN-HPβCD formulations
The solubility of IN in a wide variety of lipids was visually evaluated to select suitable
lipid excipients for formulating the SLNs/NLCs. Solid lipid, namely Compritol® 888 ATO, was
melted, and IN (5% w/w with respect to the lipid) was dissolved therein to obtain a clear lipid
phase. Simultaneously, an aqueous phase prepared using the surfactants poloxamer 188 (0.25%
w/v) and Tween® 80 (0.75% w/v) and glycerin (2.25% w/v) in bidistilled water, was heated. The
hot aqueous phase was added to the melted lipid phase while stirring, and the premix was then
subjected to emulsification at 16,000 rpm for 6 min using a T 25 digital Ultra-Turrax. The preemulsion obtained was homogenized under high pressure, using previously optimized process
parameters (15-20 K psi; 6 cycles; 6 min), using a thermostated Emulsiflex C5 (Avestin) resulting
in the formation of a hot emulsion dispersion (42). The hot emulsion obtained was slowly cooled
to room temperature to form the IN-SLNs. The final concentrations of Compritol® 888 ATO and
IN in the formulation were kept constant at 2% w/v and 0.1% w/v, respectively.
Additionally, a variation of the IN-SLN formulation was prepared wherein 2.5% w/v
HPβCD (final concentration) was added to the aqueous phase described above prior to the
preparation of the SLNs. The pH of the resulting formulations was adjusted to 6.8 using NaOH
(1N).
Indomethacin nanostructured lipid carriers (IN-NLCs)
The NLCs contained both solid (Compritol 888® ATO) and liquid lipids (Miglyol® 812 or
829), unlike the SLNs, which contained only solid lipids. The total amount of lipid employed in
the NLCs was 4 and 8% w/v, of which Compritol 888® ATO constituted 60% and Miglyol® 812
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or 829 made up the remaining 40% of the lipids. The concentration of surfactants (Tween 80® and
poloxamer 188) and propylene glycol in the NLC formulations were maintained identical to that
in the SLNs. Drug loading in all NLC formulations was kept constant at 0.8% w/v.
Chitosan-coated IN solid lipid nanoparticles (IN-CS-SLNs)
CS (mol. wt. < 200 kDa) was used for surface modification of the SLNs. CS (0.1% w/v)
was incorporated into the aqueous phase prior to preparation of the SLNs, as described above (in
vitro studies). CS at a concentration of 0.25% w/v was used in the SLNs for the in vivo
experiments. Surface modification of the CS-coated formulations was confirmed through zeta
potential measurements.
2.1.4. Particle size, polydispersity index (PDI) and zeta potential measurements
The hydrodynamic radius and the PDI of the SLN dispersion, the IN-CS-SLNs and the INNLCs were determined by photon correlation spectroscopy using a Zetasizer Nano ZS Zen3600
(Malvern Instruments, Inc.) at 25°C and with 173° backscatter detection in disposable folded
capillary clear cells. Zeta potentials were measured at 25°C in folded capillary cells using the same
instrument. To measure the particle size distribution and zeta potential, the SLN samples were
diluted (1:500) with bidistilled and 0.2 µ filtered water.
2.1.5. Assay and entrapment efficiency (EE)
The lipid in the IN-SLN dispersion, the IN-CS-SLNs and the IN-NLCs was precipitated
using 190-proof alcohol (“over proof’’), or 95% alcohol by volume (“ABV”), and the drug content
in the supernatant after centrifugation (13,000 rpm for 20 min), as such or after further dilution
with 190-proof alcohol, was measured using an HPLC system.
The percentages of IN entrapped (% EE) in the IN-SLNs and IN-NLCs were determined
by measuring the concentration of free drug in the aqueous phase of an undiluted formulation. The
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EE was evaluated by an ultrafiltration technique with a 100-kDa centrifugal filter device that
included a regenerated cellulose membrane (Amicon Ultra). A 500- μL aliquot of the
corresponding formulation was added to the sample reservoir and centrifuged at 5,000 rpm for 10
min. The filtrate was then further diluted with 190-proof alcohol and analyzed for drug content
using HPLC-UV (Section 2.1). The % EE was calculated using Eq. (1).
% EE = [

Wi−Wf
Wi

] ×100

(1)

Where Wi is the total drug content, and Wf is the amount of free drug in the aqueous phase.
2.1.6. Terminal moist-heat sterilization and stability assessment of IN formulations
Two batches each of the optimized IN lipid-based formulations, namely the IN-SLNs, the
IN-CS-SLNs and the IN-NLCs, were prepared and subjected to moist-heat sterilization (121°C for
15 min at 15 psi) in appropriately labelled glass vials using a thermo-controlled autoclave
(AMSCO® Scientific Model SI-120). Following autoclaving, the sterilized samples were evaluated
in terms of their physical appearance, color, particle size and physicochemical characteristics
compared to un-sterilized reference formulations that were maintained at room temperature.
Additionally, three batches of IN-SLNs, IN-CS-SLNs and IN-NLCs were evaluated for
their physical and chemical stability upon storage for a period of 3 months at 40°C/60% RH,
25°C/75% RH and 4°C. The particle size, PDI, zeta potential, EE and drug content were evaluated,
as described in Sections 2.1.4 and 2.1.5.
2.1.7. Fourier transform infrared spectroscopy (FTIR)
The infrared spectra (IR) of the SLN and NLC formulations were obtained using Cary 660
series FTIR (Agilent Technologies) and MIRacle ATR (attenuated total reflectance) systems. The
ratios of drug and lipids used in this set of studies were similar to the weight ratios in the IN lipid
formulations.

15

2.1.8. In vitro release studies
In vitro release profiles of IN from the respective formulations, such as the IN-Tween® 80
solution (IN-TSOL), the IN-SLNs and the IN-NLCs (F-1 and F-2), were evaluated using ValiaChien cells (PermeGear, Inc.). Spectra/por® dialysis membranes (3.5K MWCO) were mounted on
diffusion cell chambers and securely fastened with air tight clamps between the donor and receptor
chambers through which the transport or release kinetics were being studied. The temperature of
the cells was maintained at 34°C using a circulating water bath. Five milliliters of isotonic
phosphate buffer (IPBS) (pH 7.4) containing 2.5% w/v RMβCD was used as the receptor media
during the course of the study (6 hrs). Five hundred microliters of formulation was added to the
donor chamber. The, 600-µL aliquots were withdrawn from the receiver chamber at predetermined
time points and replaced with an equal volume of the 2.5% w/v RMβCD in IPBS (pH 7.4) solution.
The donor concentration was maintained at 0.1% w/v in all the formulations. The samples taken
were analyzed using a HPLC-UV system, as described in Section 2.1.2.
2.1.9. In vitro corneal permeation studies
Corneas excised from whole eyes, obtained from Pel-Freez Biologicals, were used for the
determination of in vitro transcorneal permeability. The whole eyes were shipped overnight in
Hanks’ balanced salt solution over wet ice and were used immediately upon receipt. The corneas
were excised with some scleral portion adhering to help secure the membrane between the
diffusion half-cells during the course of the transport study. After excision, the corneas were
washed with the IPBS (pH 7.4) and mounted on side-by-side diffusion half-cells (Perme Gear,
Inc®) with the epithelial side facing the donor chamber. The temperature of the half-cells was
maintained at 34°C via a circulating water bath. The IN contents in the IN-SLN, IN-CS-SLN and
IN-NLC formulations were 0.1% w/v, 0.1% w/v and 0.8% w/v, respectively. Three milliliters of
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the optimized IN-SLNs, IN-CS-SLNs or IN-NLCs was added to the donor chamber after adjusting
the pH to 6.8. The donor IN concentration was maintained at 0.1% w/v in the SLN formulation
and 0.8% w/v in the NLC formulation. The receiver chamber medium consisted of 3.2 mL RMβCD
(2.5% w/v) in IPBS solution for all the transport studies. The contents of both chambers were
stirred continuously with a magnetic stirrer. Aliquots (600 μL) were withdrawn from the receiver
chamber at predetermined time points up to 3 hrs and replaced with an equal volume of 2.5% w/v
RMβCD in IPBS. The samples were stored at −80°C until further analysis of IN using the
chromatography system described in Section 2.1.2. Additionally, the transcorneal permeabilities
of IN from the IN-SOL formulation (control) and IN-HPβCD in the presence of CS as a penetration
enhancer were also determined.
2.1.10. Trans-SCR permeability studies of IN formulations
The scleral tissue with the retinal pigmental epithelium and choroid layers excised from
whole eyes, obtained from Pel-Freez Biologicals, were used to determine the in vitro trans-SCR
(sclera-choroidal RPE) permeability of IN from the formulations. After excision, the scleral
membranes were washed with IPBS (pH 7.4) and mounted on Valia-Chien cells (Perme Gear,
Inc®). The scleral tissues were mounted as an inverted cup onto diffusion cells between the donor
and receptor chamber and fastened securely with air tight clamps such that the scleral membrane
was exposed to the donor compartment (episcleral side) and the RPE-choroidal tissues were in
contact with the receptor compartment (vitreous body side). Five milliliters of 2.5% w/v RMβCD
solution prepared in IPBS (pH 7.4) was used as the media in the receiver chamber during the course
of the study for 2.5 hrs. Five hundred microliters of IN-SOL, IN-HPβCD, IN-SLNs (pH 6.8 and
7.4), and IN-SLNs+HPβCD were added to the donor chambers, and the concentration was
maintained at 0.1% w/v. Aliquots (600 μL) were withdrawn from the receiver chamber at
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predetermined time points (15, 30, 45, 60, 90, 120 and 150 min) and replaced with an equal volume
of receiver medium. The samples taken were analyzed using the HPLC-UV system as discussed
in Section 2.1.2.
2.1.11. In vivo bioavailability studies
In vivo bioavailability of IN was determined in Male New Zealand White albino Rabbits,
weighing between 2-2.5 kg, procured from Harlan Labs. All the animal studies conformed to the
tenets of the Association for Research in Vision and Ophthalmology statement on the use of
animals in ophthalmic vision and research and the University of Mississippi Institutional Animal
Care and Use Committee approved protocols. Rabbits were anesthetized using a combination of
ketamine (35 mg/kg) and xylazine (3.5 mg/kg) injected intramuscularly and were maintained under
anesthesia throughout the experiment. The IN formulations, namely the IN-SOL, IN-HPβCD, and
IN-SLNs, were evaluated in vivo. All the above IN topical formulations (100 µL) were given as
two doses (50 µL), 30 min apart, (T-30 min and 0 min) to reduce precorneal loss. Additionally,
the IN-CS-SOL, IN-SLNs, IN-CS-SLNs (n=6) and IN-NLCs were administered to conscious
rabbits to delineate the effects of anesthesia on the ocular bioavailability of IN. CS was used at a
concentration of 0.25% w/v (in vivo). Two hours post-topical application, the rabbits were
euthanized with an overdose of pentobarbital injected through a marginal ear vein. The eyes were
washed thoroughly with ice-cold IPBS and were immediately enucleated. All the intraocular
tissues were separated and stored at -80°C, and further analysis was carried out using the HPLCUV system (Section 2.1.2.). All experiments were performed in triplicate.
2.1.12. Biosample preparation for the determination of IN content in ocular tissue
homogenates
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The in vitro analytical HPLC-UV method described above was employed for sample
analysis following method validation. A protein precipitation technique was employed to
determine the amount of IN in the ocular tissue homogenates. Briefly, tissues including the cornea,
sclera, iris-ciliary (IC), and retina-choroid (RC) were cut into small pieces, and a mixture of icecold acetonitrile and 0.1% v/v formic acid was added (1 mL) to precipitate proteins from each
individual tissue. The supernatant was then collected via centrifugation for 1 hr at 13000 rpm prior
to the analysis. The aqueous humor (AH) (200 µL) and vitreous humor (VH) (500 µL) were
precipitated by adding an ice-cold mixture of acetonitrile and formic acid, 200 µL of each for the
AH and 500 µL of each for the VH corresponding to a ratio of 1:1. Quantification of IN was
performed using standard calibration curves constructed from various ocular tissues, such as the
cornea (20-500 ng), the sclera (20-500 ng), the AH (10-200 ng), the VH (10-200 ng), the IC (10200 ng), and the RPE (10-200 ng). All the standard curves had a coefficient of determination r2 ≥
0.96. The recovery of IN was evaluated by spiking the drug in pure AH and VH and comparing
the expected IN concentration with the standard concentration. Recovery values were determined
for AH (93.1) and VH (91.5). Interference was not observed from co-eluted protein residues with
respect to IN peaks in any of the tissues. The limit of detection (LOD) for various ocular tissues
was determined and corresponded to 10 ng for AH, 10 ng or VH, 5 ng for the cornea, 5 ng for the
sclera, 10 ng for the RPE, and 10 ng for the IC.
2.3. Data analysis
The steady-state flux (SSF) for transcorneal and trans-SCR experiments was calculated by
dividing the rate of transport by the surface area. The slope of the cumulative amount of IN
transported versus time plot was used to obtain the rate of IN transport across the excised rabbit
cornea. The flux was calculated using the Eq. (2).
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Flux(J) = (dM/dt)/A

(2)

where M is the cumulative amount of drug transported, and A is the surface area of the
corneal membrane (0.636 cm2) exposed to the permeant (drug).
The transcorneal permeability was determined by normalizing the SSF to the donor
concentration, Cd, according to Eq. (3).
Permeability(Papp) = Flux/Cd

(3)

2.3.1. Statistical analysis
One-way-ANOVA coupled with a post hoc test was employed to analyze the differences
between groups (in vivo). The difference in data obtained were considered statistically significant
at level of p<0.05.
2.4. Results
2.4.1. Morphometrical and physico-chemical characteristics
The particle size, zeta potential, PDI and EE of IN-SLN, the IN-CS-SLNs and the IN-NLCs
were observed to be 226 ± 5, 265 ± 8, and 227 ± 11 nm; -22 ± 0.8, 27 ± 1.2, and -12.2 ± 2.3 mV;
0.17, 0.30, and 0.23; and 81 ± 0.9, 91.5 ± 3.2 and 99.8 ± 0.2%, respectively. The quantitative
compositions of the various IN formulations are presented in Table 2.1. The particle size of the
IN-NLCs increased as the total lipid content increased, and IN-NLC-F1 appears to be a promising
formulation, exhibiting a lower hydrodynamic radius and better physico-chemical characteristics
compared to the other formulations (Table 2.2).
Table 2.1: Composition of IN formulations with individual components represented by weight
(mg).
IN formulations
Formulation
composition
IN (mg)

INTSOL

IN-SOL

IN-CSSOL

INHPBCD

IN-SLNHPβCD

IN-SLN

IN-CSSLN

10

10

10

10

10

10

10

20

F-1
INNLC
80

Compritol
(mg)
Miglyol®
812
Poloxamer
188 (mg)
Tween® 80
(mg)
Glycerin
(mg)
Propylene
glycol (mg)
CS (mg)
HPβCD (mg)
Water (mL)

-

-

-

-

200

200

200

260

-

-

-

-

-

-

-

140

-

-

-

-

25

25

25

25

100

100

100

-

75

75

75

75

-

-

-

-

225

225

225

225

-

2930

2930

-

-

-

-

-

10

10

10
10

250
10

250
10

10

25
10

10

Table 2.2: Composition of lipid mixtures used in the NLC formulations. The particle size
characteristics, PDI, zeta potential, entrapment efficiency and assay values for each formulation
are presented below.
IN-NLC formulations

F-1

F-2

F-3

F-4

F-5

F-6

IN (0.8% w/v)

80

80

80

80

80

80

Compritol (60%)

240

240

240

240

240

240

Miglyol 812 (40%)

160

-

320

640

-

-

Miglyol 829 (40%)

-

160

-

-

320

640

Total lipid (%; mg)

4%; 400

4%; 400

8%; 800

16%; 1600

8%; 800

16%;
1600

particle size (nm)

227

279.1

304.1

519.2

385.1

629.1

Polydispersity index (PDI)

0.235

0.259

0.433

0.58

0.456

0.381

Zeta potential (mV)

-12.2

-5.57

-0.92

0.027

-2.58

-0.304

99.8

99.74

100

100

100

99.9

96.8

97.8

97.4

91.3

96.2

92.5

Entrapment efficiency (%)
EE
Assay (%)

2.4.2. Solubility of IN in the presence of cyclodextrins and surfactants
Cyclodextrins and surfactants are frequently employed as solubilizers in topical ophthalmic
formulations. The solubilities of IN in 0.25 and 0.5% w/v poloxamer 188 at pH 7.4 were measured
as 251.8 ± 78 and 657 ± 127 µg. The solubility of IN in 0.5% w/v Tween® 80 at pH 7.4 was
determined to be 1055 ± 106 µg. The solubility profiles of IN in 5% w/v HPβCD and RMβCD
were found to be similar. However, the solubility of IN is highly pH-dependent and tends to be
predominantly solubilized at high pH (Figure 2.1).
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Figure 2.1: pH-dependent saturation solubility of IN in phosphate buffer, 5% w/v HPβCD in
phosphate buffer, and 5% w/v RMβCD in phosphate buffer (µg/mL). The results are depicted as
the mean ± SD (n=3).
2.4.3. Stability, moist-heat sterilization and FTIR studies
IN-CS-SLNs and IN-NLCs exhibited good stability when compared to the IN-SLN
formulation. The particle size of the IN-SLN formulation after storage for 90 days at 40°C was
increased by 65%, whereas the IN-CS-SLNs and IN-NLCs displayed a 15-20% increase in particle
size (Figure 2.2). Additionally, the EE of the SLN formulations decreased by 12% compared to
the IN-CS-SLNs (6%) and IN-NLCs (5%) (Figure 2.3a). The zeta potential and PDI of the IN
formulations were not changed significantly under the storage conditions tested here (Figure 2.3b
and 2.3c). Figure 2.4 shows the effect of sterilization on the physicochemical characteristics of
the IN lipid-based formulations. No significant differences were observed post-sterilization. The
particle size of the IN-CS-SLNs and IN-NLC formulations slightly increased compared to the INSLNs following autoclaving. Additionally, the FTIR spectra revealed a slight drug-excipient
interaction in the lipid formulations (Figure 2.5).
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Figure 2.2: Particle size characteristics of various IN formulations following storage at 4°C,
25°C/60% RH, and 40°C/75% RH. The data represent the mean ± S.D (n=3).

Figure 2.3a: Entrapment efficiency (% EE) of various IN formulations following storage at 4°C,
25°C/60% RH, and 40°C/75% RH. The data represent the mean ± S.D (n=3).
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Figure 2.3b: Zeta potential of various IN formulations following storage at 4°C, 25°C/60%
RH, and 40°C/75% RH. The data represent the mean ± S.D (n=3).

Figure 2.3c: Polydispersity indices (PDI) of various IN formulations following storage at
4°C, 25°C/60% RH, and 40°C/75% RH. The data represent the mean ± S.D (n=3).
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Figure 2.4: Physico-chemical characteristics of the IN SLN and NLC formulations pre
(Fig 2.4A) and post-sterilization (2.4B). The data represent the mean ± S.D (n=3).

Figure 2.5: FTIR spectral images of the IN + Compritol physical mixture, Compritol, IN,
IN-SLN, IN-CS-SLN and IN-NLC F-1 formulations.
2.4.4. In vitro release studies
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Based on the solubility profile of IN in different solubilizing agents, RMβCD in IPBS at
pH 7.4 was chosen as the receptor media for the in vitro release and transcorneal permeability
experiments. The in vitro releases of IN from the IN-TSOL, the IN-SLNs, the F-1IN-NLCs, and
the F-2 IN-NLCs were observed to be 81.6 ± 2.1 µg, 18.7 ± 0.9 µg, 31.8 ± 3.9 µg, and 23.3 ± 3.1
µg within the time period tested (6 hrs). The in vitro release of IN from these formulations is
depicted in Figure 2.6.

% IN VITRO RELEASE

100
80
60
40
20

0
0

50

100
IN-NLC F-1

150
200
TIME (min)
IN-NLC F2

250
IN-TSOL

300

350

400

IN-SLN

Figure 2.6: In vitro release of IN from various formulations across Spectra/Por® membranes at
34°C. Receiver solution consisted of IPBS containing 2.5% w/v RMβCD (pH 7.4). The results are
depicted as the mean ± S.D (n=3).
2.4.5. Transcorneal permeability studies
The transmembrane permeabilities of IN from the IN-SLNs, the F-1IN-NLCs, and the F-2
IN-NLCs were observed to be 1.93 ± 0.17 x 10-5, 1.34 ± 0.13 x 10-5, and 1.2 ± 0.1 x 10-5 cm/s,
respectively. The transcorneal flux of IN was increased by two-fold when CS was used as a
permeation enhancer in the SLN formulation. Moreover, the effect of including CS as a penetration
enhancer in the solution formulations, namely in IN-SOL and IN-HPβCD, was also investigated.
CS significantly enhanced the transcorneal flux of IN by ~3.5 and ~2-fold for the IN-SOL and INHPβCD formulations, respectively (Figure 2.7).
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Figure 2.7: Transcorneal flux across isolated rabbit cornea from various IN topical formulations
at 34ºC. The receiver solution consisted of IPBS containing 2.5% w/v RMβCD (pH 7.4). The
results are depicted as the mean ± S.D (n=4).
2.4.6. Trans-sclera-choroid-RPE (SCR) permeability studies
Trans-SCR permeability experiments were carried out to assess the scleral penetration
capability of IN from the formulations compared to the corneal absorption route. The trans-SCR
permeability of IN-HPβCD was markedly higher compared to IN-SOL. The trans-SCR
permeabilities of the SLN increased in the order of IN-SLNs (pH 6.8) < IN-SLNs (pH 7.4) < INSLNs + HPβCD (pH 6.8). The SLNs in combination with HPβCD demonstrated a higher trans-
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Figure 2.8: Trans-SCR permeability of IN from various topical ocular formulations at 34ºC.
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The receiver solution consisted of IPBS containing 2.5% w/v RMβCD (pH 7.4). The results
are depicted as the mean ± S.D (n=3).
2.4.7. In vivo bioavailability studies
Based on the transcorneal and trans-SCR data obtained, the IN formulations were
investigated for their ocular bioavailability and disposition of IN 2 hrs post-topical administration
in anesthetized and conscious rabbits. The IN-SOL formulation could not deliver the drug to the
posterior ocular tissues. However, the IN-SOL formulation was able to achieve drug levels in the
anterior segments of the eye, including 463.5 ± 15 ng/g in the cornea and 224 ± 8.6 ng/g in the
scleral tissues. CS as a penetration enhancer further improved the ocular bioavailability of INSOL. Significant drug levels were attained from the IN-HPβCD formulation in most of the ocular
tissues tested, namely in the cornea (3267.3 ± 1867.6 ng/g), the sclera (575.7 ± 433.5 ng/g), the
AH (877.4 ± 492.5 ng/g), the RC (94.4 ± 79.9 ng/g) and the IC (1203.9 ± 547 ng/g). Significantly
higher levels of IN were observed in the posterior segments of the eye for the use of the SLN
formulation compared to the IN-SOL and IN-HPβCD formulations. The formulation of SLNs in
combination with 0.25% w/v CS achieved higher levels of IN in conscious rabbits (n=6). The NLC
formulations, however, were the most effective in terms of drug loading and ocular IN levels. The
ocular tissue IN concentrations obtained from the above formulations are shown in Figures 2.9
and 2.10.
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Figure 2.9: IN ocular tissue concentrations (ng/g of tissue) obtained from the IN-SOL, INHPβCD, and IN-SLN formulations 2 hrs post-topical administration in the anesthetized rabbit
model. The data represent the mean ± S.D. (n=3). AH: Aqueous humor; VH: Vitreous humor;
IC: Iris-Ciliary; RC: Retina-Choroid. (N.D., not detected). Different symbols, such as µ and β,
indicate significant differences (p<0.05) of the IN-HPβCD and IN-SLN formulations compared
to IN-SOL. ¥ represents a significant difference in the ocular tissue concentrations of IN for use
of the IN-SLNs compared to all other formulations.

Figure 2.10: IN ocular tissue concentrations (ng/gm of tissue) obtained from the IN-CS-SOL, INSLN, IN-CS-SLN (n=6) and IN-NLC formulations 2 hrs post-topical administration in the
conscious rabbit model. The data represent the mean ± S.D. All the experiments were performed
in triplicate if not indicated otherwise. Different symbols, such as ¶ and β, indicate significant
differences (p<0.05) of the IN-SLN and IN-CS-SLN formulations compared to IN-CS-SOL. ¥
represents a significant difference in the ocular tissue concentrations of IN for use of the INNLCs compared to all other formulations.
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2.5. Discussion
The objective of the current work was to develop IN-loaded lipid-based nanoparticles and
to investigate the in vitro corneal permeation and in vivo ocular disposition of IN from these
formulations. Most NSAIDs are inherently weak acidic drugs with poor corneal penetration due
to their ionization at lacrimal pH. Lowering the pH of these formulations increases corneal
penetration but also increases potential irritation. Additionally, it has been reported that due to the
anionic nature of NSAIDs, they are incompatible with preservatives such as benzalkonium
chloride and could form insoluble complexes (54-56). IN (pKa of 4.5) exhibits pH-dependent
solubility, which increases as a function of higher pH (acidic to neutral/alkaline: 1.5 µg/mL at pH
1.2 and 105.2 µg/mL at pH 7.4). IN displayed a solubility of 0.64 ± 0.02 mg/mL in phosphate
buffer at pH 7.0, which is consistent with previously reported data (57, 58). Additionally, the
solubility of IN was increased by ~5 and ~6-fold with 5% w/v HPβCD and RMβCD in phosphate
buffer at pH 7.0.
SLNs and NLCs are colloidal nanoparticulate dispersions that can be administered
topically in the form of eye drops. A major advantage of the nanoparticulate systems is their uptake
by epithelial cells, which allows for greater penetration into the surface layers (59-61). Moreover,
the small size, biocompatibility and mucoadhesive properties of SLNs improve their interactions
and prolong the pre-ocular residence time of drugs, thus enhancing drug bioavailability (62, 63).
The literature suggests that surface modification of SLNs by coating with hydrophilic agents such
as poly (ethylene) glycol derivatives (PEGs) or chitosan can further improve ocular penetration,
mainly due to enhancing interactions with the ocular mucosa and increasing cellular uptake and
internalization (64, 65). Additionally, previous reports have demonstrated the ability of chitosan
nanoparticles to produce a sharp, reversible decrease in the transepithelial electrical resistance
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(TEER) and to improve the permeability of model macromolecules (66). The mechanism of
mucoadhesion is possibly through the electrostatic interaction between the positively charged
amino groups of chitosan and the negatively charged sialic acid residues of ocular mucosa (67).
The corneal route is a major absorption pathway for topically administered medications
(68). Compared to other formulations, IN-SLNs demonstrated higher transcorneal permeability,
which may be ascribed to endocytosis or transcytosis uptake mechanisms (69, 70). The in vitro
transcorneal permeability of IN from the NLC formulations was comparatively lower than that of
the SLNs, probably because of higher entrapment in the oily phase and thus lower partitioning into
the membrane. Reports have suggested that chitosans with a moderate degree of deacetylation (6580%) and a relatively high molecular weight (170-200 kDa) is required for the exertion of optimal
transepithelial penetration and low toxicity (71-73). The in vitro transcorneal flux of IN from the
IN-SOL, IN-HPβCD, and IN-SLN formulations increased by ~3.5-fold, ~2-fold and ~2-fold,
respectively, in the presence of CS, which is consistent with previous reports.
Numerous reports have demonstrated that sclera is more permeable to hydrophilic than to
lipophilic molecules and approximately 10 times more permeable than the cornea (74, 75). Based
on trans-scleral transport studies, the higher permeability across several static layers of ocular
tissues (sclera, Bruch’s membrane-choroid, RPE, and neural retina) demonstrates the diffusional
ability of drugs to the back of the eye through the conjunctival-scleral pathway (76, 77). To
investigate drug delivery to the posterior ocular segments, scleral diffusion of IN was assessed in
trans-SCR experiments. The higher observed trans-scleral permeability of IN from the SLNs
compared to the IN-SOL and IN-HPβCD formulations demonstrated that lipid carriers could
enhance accumulation in scleral tissue, prolonging the ocular residence time in vivo. The increased
permeability of IN from SLNs with HPβCD in external aqueous phase could be due to the
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complexation effect of cyclodextrin with the free drug. The trans-scleral permeability of SLNs at
pH 7.4 (2.99 ± 0.1 x 10-5 cm/s) was considerably higher than that of the SLNs at pH 6.8 (2.13 ±
0.3 x 10-5 cm/s), which is likely due to an increase in the ionized fraction of IN at pH 7.4.
Castelli et al. (78) fabricated SLNs and NLCs of IN and characterized the formulations
with respect to drug distribution and entrapment efficiencies in the lipid matrices. However, the
loaded drug in the SLNs and NLCs of IN was maintained at 2 and 1.5% w/w with respect to the
total lipid, whereas in the present study, drug loading of IN in the SLNs and NLCs was achieved
at 5 and 20% w/w, respectively. The IN lipid formulations demonstrated higher drug loading and
entrapment efficiencies at lower lipid contents compared to Castelli’s formulations. Bucolo et al.
(79) investigated the ocular pharmacokinetics of IN following a multiple dosing treatment regime
(30 µL/eye; four times in 8 hrs) of 0.5% IN + hydroxypropylmethylcellulose, IN-HPMC and
Indocollyre® eye drops in conscious rabbits. The drug levels in the AH, RC and VH obtained 2 hrs
post-topical administration of IN-HPMC and Indocollyre® solution were 360 ± 40 and 100 ng/mL,
65 and 20 ng/g, and 7± 2 and 5 ± 2 ng/mL, respectively. Campos et al. (67) studied the ocular
distribution of chitosan-fluorescein nanoparticles (0.25% w/v, dose: 100 µL, 250 µg) and their
interaction with the corneal and conjunctival epithelia in conscious rabbits. The drug levels in the
cornea and conjunctiva 2 hrs post-topical application were 760 ± 60 and 1000 ± 150 ng/g,
respectively. In another study, Klang et al. (80) formulated positively charged submicron
emulsions (0.1% w/v) and compared the formulation with Indocollyre®. The drug concentrations
obtained in the cornea and conjunctiva 1 hr after topical instillation of 50 µL of the test formulation
were nearly 40 and 30% lower, respectively, compared to the marketed formulation. The drug
concentrations obtained in the AH and sclera-retina were found to be 75 ± 38 ng/mL and 800 ±
310 ng/g (submicron emulsion) vs 110 ± 50 ng/mL and 450 ± 200 ng/g (Indocollyre®),
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respectively. Yamaguchi (81) et al. investigated ocular tissue IN concentrations upon use of
chitosan-coated emulsion (0.1% w/v) formulations 1 hr post-topical instillation (50 µL) in both
eyes of anesthetized male Japanese albino rabbits. The drug levels attained were predominantly in
the cornea (3596±425 ng/g), aqueous humor (434±90 ng/mL) and conjunctiva (668 ± 188 ng/g).
In another study, an IN (0.1% w/v) ophthalmic solution was prepared using Poloxamer® 407 (10%
w/w) and compared with an Indocollyre® formulation in terms of AH concentration 2 hr after a
multiple post-topical administration regime of 150 µL (6 x 25 µL at 90 sec intervals). The IN
concentration in the AH was enhanced by ~2-fold compared to the use of Indocollyre® (40).
In comparison to all the ocular tissue levels obtained with the above-discussed
formulations, the IN-CS-SLNs delivered significantly higher levels of IN to the anterior and
posterior segment ocular tissues, which could be attributed to mucoadhesive and epithelial barriermodulating properties of chitosan. Compared to IN-SOL without CS, the incorporation of CS in
the IN-SOL formulation improved penetration of IN into the AH and IC bodies, but retinal tissue
IN levels remained below the detection limit. The addition of viscosity modifiers, such as
hydroxypropyl methylcellulose, in the IN-CS-SOL formulation may further prolong the precorneal
residence and thus increase ocular drug levels. IN concentrations were reduced by ~4- to 5-fold in
conscious animals compared to the anesthetized model, delineating the effects of anesthesia on
ocular pharmacokinetics. In comparison, at higher doses (0.8% w/v; 8-fold dose) the IN-NLCs
delivered ~4- to 5-fold higher concentrations than the IN-CS-SLNs, which could be due to higher
drug loading, EE and pre-ocular retention of IN for the use of the NLC formulation. NLCs are
superior to SLNs in terms of higher drug loading, higher EE, improved storage stability and less
drug expulsion during storage.
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The effect of storage conditions and sterilization on the morphometrical and physicochemical characteristics of IN formulations are shown in Figures 2.2-2.4. There was initially no
significant difference in particle size, zeta potential, or PDI between the SLNs and NLCs, but as
the time progressed, the IN-NLC and IN-CS-SLN formulations were found to be more stable than
the IN-SLNs. The EE of the formulations decreased slightly as the storage time increased, although
the change was not statistically significant (Figure 2.3a). Sterilization trials suggested that the IN
lipid-based formulations were autoclavable (Figure 2.4). A qualitative FTIR spectral analysis was
employed to investigate any interactions and/or incompatibility among the lipid, drug and other
excipients. The FTIR spectra of the physical mixture indicated slight molecular interactions
between the drug and Compritol. The characteristic peaks of IN at 1,711 cm-1 (carbonyl stretchingacid group), 1,221 cm−1 (asymmetric aromatic O–C stretching) and 1,086 cm−1 (symmetric
aromatic O–H stretching) are masked in the formulations possibly due to the amorphous transition
and entrapment of IN in the lipid matrices. In conclusion, the results obtained here indicate that
lipid-based systems can dramatically improve the transcorneal permeability and retention
characteristics of IN compared to conventional formulations in vivo. Thus, colloidal frameworks
could be exploited to enhance ocular bioavailability significantly, including back-of-the-eye ocular
tissues.
2.6. Conclusion
Targeting NSAIDs to the posterior segment of the eye via a topical route is a challenging
task due to formulation constraints and the anatomical, physiological and efflux barriers present
in ocular tissues. IN-loaded NLC formulations displayed higher drug-loading capabilities and
entrapment efficiencies, which resulted in higher IN levels in the ocular tissues. The IN-CS-SLNs
demonstrated superior trans-membrane IN permeation characteristics compared to the IN SLNs,
confirming the penetration-enhancing properties of chitosan. It is worth noting that the IN-CS34

SLNs, containing a tenth of the loaded drug of the IN-NLCs, induced IN concentrations in the
inner ocular tissues (the AH, IC and RPE-choroid) that were 3- to 4-fold lower than those obtained
for IN-NLCs. The corneal and scleral IN concentrations achieved using the IN-NLCs were
significantly higher, indicating the effect of the increased drug loading in the formulation. Thus,
both the IN-CS-SLNs and IN-NLCs are viable platforms for the posterior ocular delivery.
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CHAPTER 3
OCULAR DISPOSITION OF CIPROFLOXACIN FROM TOPICAL, PEGYLATED
NANOSTRUCTURED LIPID CARRIERS: EFFECT OF MOLECULAR WEIGHT
AND DENSITY OF POLY (ETHYLENE) GLYCOL
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3. Introduction
Delivery of drugs, especially to the back-of-the eye tissues comprising sclera, choroid,
retina, and vitreous body, is restricted by multiple physiological processes, anatomic, static,
dynamic and efflux barrier functionalities (1, 82). Efflux protein pumps expressed on ocular tissues
restrict transmembrane permeability of drugs, thus lowering penetration of substrates from the
systemic, topical or periocular routes (83, 84). Topical application is the most favored route
because of the ease of administration, lack of associated complications and minimal non-specific
systemic exposure. Only 5-10% of the topically administered dose, however, reaches the inner
ocular tissues (85, 86). Although advances have been made with respect to delivery into the
anterior segment ocular tissues, significant challenges still exist for very lipophilic molecules in
view of the formulation restrictions placed by the sensitivity of the ocular tissues. Several
formulation approaches such as inclusion of viscosity enhancers in aqueous ophthalmic solution
or suspension formulations, ion-exchange resin based formulations, implants, transporter targeted
systems, emulsions, films and other nanoparticle mediated drug delivery strategies have been
described in the literature, and some are commercially available (87-90). Despite technological
advancements in the formulation strategies, delivery of therapeutic agents efficiently into the backof-the eye ocular tissues through the topical route remains elusive (91). Ointments have been
successful to some extent but various drawbacks, including difficulty in application and problems
in vision, have limited its usefulness. Success in back-of-the eye delivery mainly depends on
formulation platform, candidate’s physicochemical properties and absorption pathway.
Penetration of drugs across alternatively polarized (lipophilic and hydrophilic) ocular layers, and
through the corneal tight junctions, is highly dependent upon their physicochemical properties.
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Thus, the molecules should exhibit optimum physicochemical aspects and are to be formulated in
appropriate dosage forms for enhanced retinal delivery (92, 93).
Kinetics, bio-distribution and release profile of drugs could be dramatically modulated with
nano particulate systems (94, 95). Nanoparticles have been observed to exhibit superior
penetration characteristics into the inner ocular tissues compared to solution or suspension
formulations (96). Lipid based systems such as nanostructured lipid carriers (NLCs) are potential
carriers for therapeutic agents, especially hydrophobic molecules, and possess favorable properties
including but not limited to biocompatibility, mucoadhesion, penetration /retention capability,
lower clearance rate, controlled release, greater stability and protection of the drug candidate from
chemical degradation. NLC’s can be formulated from a wide variety of lipids (solid/liquid) and
phospholipid combinations with varying composition, to achieve desired morphometrical,
physicochemical, surface charge and release characteristics. Mixture of solid and liquid lipids used
in NLC’s create imperfections in the crystal lattice accommodating higher drug loads while
maintaining similar penetration capabilities as the solid lipid nanoparticulates (SLNs). In addition,
NLCs allow higher drug loading compared to SLNs, exhibit better encapsulation efficiency, lesser
drug expulsion and higher stability (97-99). Reports suggest that PEGylated amphiphilic lipids
possess the ability to transform into lipid based lyotropic crystals with thermodynamically stable
self-assembled structures in aqueous environment (100, 101). In recent years, PEGylation
technology (functionalization of nano carriers with PEG’s and appropriate ligands) has been
widely used to improve the pharmacokinetics, bioavailability and tissue distribution characteristics
of a variety of nanoparticles, because the hydrophilic and inert PEG creates a steric barrier on the
surface of nanoparticles and minimizes protein binding (102). The bulky and highly hydrated
corona of the PEG extending from the lipid bilayer into the aqueous phase is critical for enhancing
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steric stabilization of the nanoparticles (103). Also, incorporation of PEG could allow better
stabilization against aggregation, on storage and on sterilization - by amorphization and inducing
imperfections in crystal lipid lattices (104, 105).
Ciprofloxacin (CIP) belongs to class of fluoroquinolone antibiotics and is active against a
broad spectrum of gram-positive and gram-negative bacteria. It is usually prescribed as the first
line of treatment for corneal keratitis, allergic conjunctivitis and other bacterial infections of the
eye. CIP is a zwitterion with pKa values of 6.0 (acidic group) and 8.8 (basic group) and an
isoelectric point of 7.2 where it is least soluble (neutral species). The compound is currently
marketed as an ophthalmic solution and needs frequent dosing due to its poor ocular bioavailability
(106). Because of solubility issues, the formulation has to be maintained at an acidic pH. On topical
application, however, because of the buffering action of the tear fluid, the pH of the instilled
formulation is quickly neutralized as a result of which the solubility of CIP in that environment is
significantly reduced and precipitation can take place. Consequently, penetration of CIP into the
interior ocular tissues is hampered. In general, there exists a need to enhance drug penetration into
the ocular tissues through the topical route. Moreover, improved delivery and penetration of ocular
drugs with solubility issues, such as CIP, would be highly beneficial for intervening in
complications associated with bacterial infections.
The objective of the current research is to assess the effect of type and density of surface
PEGylation of CIP loaded NLCs in terms of process (including autoclave sterilization) and storage
stability characteristics and ocular disposition.
3.1.

Materials and Methods
CIP was obtained from Sigma Aldrich (St. Louis, MO). DSPE-mPEG-1000, DSPE-mPEG-

10000, DSPE-mPEG-20000, (N-Carbonyl-methoxypolyethylene glycol-5000)-1,2 di-myristoyl-
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sn-glycero phosphoethanolamine (DMPE-mPEG-5000) were received from Creative PEG Works
(Winston Salem, NC). 1,2-dipalmitoyl-sn-glycero phosphoethanolamine (DPPE), DMPE-mPEG2000, and DPPE-mPEG-2000 were obtained from NOF America Corporation (White Plains, NY).
DSPE-sodium (C18), DMPE- sodium (C14), DPPE- sodium (C16), DSPE-mPEG-2000 and DSPEPEG-5000 were obtained from Lipoid® (Ludwigshafen Germany). Glyceryl Monostearate was
obtained as a gift sample from Gattefossé (Paramus, NJ). Amicon® Ultra centrifugal filter devices
with regenerated cellulose membrane (molecular weight cut off 100 kDa), Poloxamer 188,
Tween®80, high performance liquid chromatography (HPLC) - grade solvents, and other
chemicals (analytical grade) were obtained from Fisher Scientific (Hampton, NH). Whole eyes of
male albino New Zealand rabbits were obtained from Pel-Freez Biologicals (Rogers, AR). Male
albino New Zealand rabbits were procured from Harlan Labs (Indianapolis, IN).
3.1.1. Formulations
CIP-NLCs and PEGylated CIP-NLCs (PEG-CIP-NLCs)
Glyceryl monstearate (GMS), DSPE-sodium C18 (phospholipid) and oleic acid (liquid
lipid) were used to prepare the DSPE-CIP-NLCs by ultra-sonication method. Briefly, GMS and
oleic acid were melted, DSPE-sodium salt was added in small increments to form homogenous
lipid mixture and then CIP was dispersed therein to obtain a lipid phase. An aqueous phase,
containing surfactants (Poloxamer 188 (0.25% w/v) and Tween® 80 (0.75% w/v) and glycerin
(2.25% w/v) in bi-distilled water, was heated. The hot aqueous phase was then added to the melted
lipid phase under stirring to form a premix. The premix was then sonicated at 16,000 rpm for 6
min using T 25 digital Ultra-Turrax to form a hot pre-emulsion. The pre-emulsion obtained, was
subjected to ultra-sonication (VibracellTM) at an amplitude of 80 for 6 min resulting in the
formation of hot emulsion dispersion. The hot emulsion obtained was slowly cooled to room
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temperature to form NLCs. The pH of the resulting formulation was adjusted to 5.0 using 0.1 N
NaOH.
A portion of the phospholipids in the DSPE-CIP-NLC formulations were replaced with
PEGylated phospholipids, N-(Carbonyl-methoxypolyethylene glycol-2000)-DSPE (DSPEmPEG2000), to prepare the PEG-CIP-NLCs (PEG(2K)-CIP-NLC). Total amount of the lipid in
the NLCs was 6% of which solid lipid constituted 50% and oleic acid made up the remaining 50%.
Drug load in the formulations was maintained at 0.3% w/v.
Additional PEG-CIP-NLCs were prepared wherein the molecular weight of the PEG (1K,
2K, 5K,10K and 20K) grafted to DSPE was varied (DSPE-mPEG-1K / DSPE-mPEG-5K /DSPEmPEG-10K / DSPE-mPEG-20K) to study the effect of the PEG molecular weight on the
biopharmaceutical characteristics of the NLCs. CIP formulations were also prepared with mPEG2K derivatized phospholipids of different chain lengths such as PEG 2000-1,2dimyristoyl/dipalmitoyl-sn-glycero-3-phosphoethanolamine, sodium salt (DMPE C14 / DPPE C16).
These formulations, wherein the PEG molecular weight is constant (2K) but the lipid chain length
is different (DPPE and DMPE), were designed to understand the role of the phospholipid chainlength on the PEG-CIP-NLC characteristics. A detailed description of the composition of all the
CIP-NLC and PEG-CIP-NLC formulations tested, including the associated formulation codes
used, have been presented in Table 1. All the components (lipids/surfactants) used in the
formulations are represented by weight (mg).
Table 5 includes several placebo formulations (SLNs/NLCs) prepared using different lipid
(solid/liquid) mixtures (combinations varying composition and/or total lipid content) tested for
physical autoclave stability. The lipid excipients and surfactants used in the formulation are
represented by weight (mg). Two batches (n=2) of formulations each with batch size of 10.6 g
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(volume ~10 mL) were used for stability testing. NLCs that were unstable on autoclaving were
reformulated by replacing 50% of the phospholipid (DSPE) with PEGylated (2K) DSPE to yield
PEG(2K)-NLCs. The effect of PEG surface packing density (0-40%) and molecular weight (1K,
2K and 5K) on the autoclave stability of the PEG-NLCs was subsequently studied.
Chitosan coated NLCs (CIP-ChCl-NLCs) and CIP control solution
The DSPE-CIP-NLC formulation was coated with chitosan chloride (ChCl – 0.25% w/v)
by adding ChCl solution into the final formulation (Table 1). Surface adsorption was confirmed
by way of change in the zeta potential value.
CIP control formulation
Marketed CIP ophthalmic Solution 0.3% w/v was used as control formulation for the
studies (Mfg. By: Hi-Tech Pharmacal; Lot # 622553).
3.1.2. Particle size, zeta potential and polydispersity Index (PDI) measurement
The hydrodynamic radius and the PDI of the NLC formulations were determined by photon
correlation spectroscopy, using Zetasizer Nano ZS Zen3600 (Malvern Instruments, Inc.) at 25°C
and 173° backscatter detection, in disposable clear cells. The measurements were obtained using
a helium-neon laser of 633 nm, and the particle size analysis data was evaluated using volume
distribution. Zeta potential measurements were carried out at 25°C in disposable cells using the
same instrument. For measurement of particle size distribution and zeta potential, NLC samples
were diluted (1:500) with water. Bi-distilled and 0.2 μM filtered water was used for these
measurements, and were performed in triplicates.
3.1.3. Scanning transmission electron microscopy (STEM) studies
Lipid nanoparticulate formulations were characterized by scanning transmission electron
microscope (Zeiss Auriga®-40 dual beam) using 1% w/v uranyl acetate as a stain. A freshly glow
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discharged 200 mesh copper grid with a thin carbon was used as a base support for the sample. A
small drop (10-20 µL) of sample was placed on a piece of parafilm and the grid was floated on top
of the sample for 30 sec, then the grid was removed and excess sample was blotted using a piece
of filter paper. Grid was then floated on a drop of distilled water for 10 sec, the water was removed
and the grid with sample was floated on a drop of stain for 1 min after which excess stain was
blotted again. After drying for at least 30 min, the samples were imaged in a Zeiss Libra operating
at 30kV and in STEM mode.
3.1.4. Analytical method for in vitro sample analysis
Samples were analyzed for CIP content using an HPLC-UV method. The system comprised
of Waters 717 plus Autosampler, Waters 2487 Dual λ Absorbance detector, Water 600 controller
pump, and Agilent 3395 Integrator. A Phenomenex Luna® C18 4.6 mm x 250 mm column was used
under isocratic elution for chromatographic analysis. The mobile phase used was mixture of
acetonitrile and triethanolamine buffer (150:850 v/v) with pH adjusted to 2.36 using orthophosphoric acid. Triethanolamine buffer is made up of water, triethanolamine and 25 mM
phosphoric acid in the ratio of (996:1.6:1.57 v/v). The flow rate was set at 1 mL/min with
λmax (detection wavelength) of 299 nm during the analysis (107).
3.1.5. Assay and Entrapment Efficiency
The assay (total drug content) is determined in the CIP NLC formulations. The lipid in the
DSPE-CIP-NLC and PEG-CIP-NLC formulations was precipitated using 50:50 binary mixture of
0.1N HCl and 190-proof alcohol and, drug content in the supernatant after centrifugation (13,000
rpm for 20 min), was measured using an HPLC system following appropriate dilution.
The percentage of CIP entrapped (% EE) in DSPECIP-NLC and PEG-CIP-NLC was
determined by measuring the concentration of free drug in the aqueous phase of an undiluted
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formulation. The EE was evaluated by an ultrafiltration technique with a 100 kDa centrifugal filter
device (Amicon Ultra). An aliquot (500 μL) of the corresponding formulation was added to the
sample reservoir and centrifuged at 5,000 rpm for 10 min. The filtrate was analyzed for drug
content using HPLC. The %EE was calculated using Eq. (1) below. All the measurements were
carried out in triplicates.
%EE = [

Wi−Wf
Wi

] ×100

(1)

Where Wi =total drug content, and Wf =amount of free drug in aqueous phase.
3.1.6. Terminal moist heat sterilization and stability assessment of CIP formulations
CIP loaded NLCs (DSPE-CIP-NLC and PEG-CIP-NLCs) and placebo formulations were
prepared and put into appropriately labelled glass vials, affixed with sterilization indicator tapes,
subjected to moist-heat sterilization (121°C for 15 min under 15 psi), in thermo-controlled
autoclave (AMSCO® Scientific Model SI-120). Stabilizing agents and cloud point modifiers such
as polyvinyl pyrrolidone (PVP K30), polyvinyl alcohol (PVA Avg Mol wt 30K -70K Da), PEG
400, PEG 1000, PEG 4000, PEG 6000 at concentrations of 0.25% and 0.5% w/v were used in the
DSPE-CIP-NLCs. Following autoclaving, sterilized samples were evaluated in terms of physical
appearance, color, morphometrical and physicochemical characteristics against unsterilized
reference formulations kept at room temperature. Sterilization cycle was confirmed by change in
the color of indicator tapes on the glass vials.
3.1.7. In vitro release studies
In vitro release of CIP from the respective formulations such as marketed CIP ophthalmic
control solution (0.3% w/v), DSPE-CIP-NLCs and PEG (2K)-CIP-NLCs were evaluated using
Valia-Chien® cells (PermeGear, Inc.). Spectra/por® membrane (3.5K MWCO) was mounted on
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diffusion cells between donor / receptor chambers and fastened with clamps, through which
transport kinetics were studied. The temperature of the cells was maintained at 34°C with the help
of a circulating water bath. Five milliliters of isotonic phosphate buffer (IPBS - pH 7.4) containing
2.5% w/v RMβCD was used as the receptor media during the course of the experiment (6 h). Five
hundred microliters of the formulations was added into the donor chamber. Aliquots (600 µL) were
withdrawn from the receiver chamber and replaced with an equal volume of the 2.5% w/v RMβCD
in IPBS (pH 7.4) solution at predetermined time points. Donor CIP concentration was maintained
at 0.3% w/v in all the formulations. Samples taken were analyzed using high performance liquid
chromatography-UV (HPLC-UV) system.
3.1.8. In vitro corneal permeation studies
The corneas excised from whole eyes, obtained from Pel-Freez Biologicals, were used for
the determination of in vitro transcorneal permeability. Whole eyes were shipped overnight in
Hanks balanced salt solution, over wet ice, and were used immediately upon receipt. The corneas
were excised with some scleral portion to help secure the membrane onto the diffusion cells. After
excision, the corneas were washed with the (IPBS; pH 7.4) and mounted on Valia-Chien cells
(PermeGear, Inc®) with the epithelial side facing the donor chamber. The temperature of the cells
was maintained at 34°C with the help of a circulating water bath. Five hundred microliters of CIP
formulations (CIP ophthalmic control solution, DSPE-CIP-NLCs and PEG (2K)-CIP NLCs was
added to the donor chamber and the CIP concentration was maintained at 0.3% w/v in
formulations. The receiver chamber consisted of 5 mL of RMβCD (2.5% w/v) in IPBS (pH 7.4)
solution for all the transport studies. Aliquots (600 µL) were withdrawn from the receiver chamber
at predetermined time points, until 3 h, and replaced with an equal volume of receiver medium.
Samples were stored at −80°C until further analysis.
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Additionally, effect of carbon chain length (DMPE / DPPE / DSPE- mPEG -2000) and
molecular weight of PEG’s (DSPE-PEG-1K / 2K / 5K) on transcorneal permeability of CIP from
PEG-CIP-NLCs was investigated using side-by-side diffusion apparatus. Three milliliter’s of CIP
formulations was added to the donor chamber and receiver medium consisted of 3.2 mL of
RMβCD (2.5% w/v) in the IPBS (pH 7.4). A slight difference in the donor and receiver chamber
volumes helped to maintain the normal corneal curvature through marginally elevated hydrostatic
pressure. The contents of both chambers were stirred continuously with a magnetic stirrer. Aliquots
(600 µL) were withdrawn from the receiver chamber at predetermined time points until 3 h and
replaced with an equal volume of the solution.
3.1.9. Biosample preparation for determination of CIP in ocular tissue homogenates
In vivo sample analysis was carried out using the HPLC-UV method mentioned above
following method validation. Mixture of ice cold acetonitrile and 0.1% formic acid (1 mL) was
added to the sample to precipitate proteins and extract the drug from individual, tissues namely
cornea, sclera, iris-ciliary (IC) and retina-choroid (RC), after cutting them into small pieces. The
samples were centrifuged for 1 h at 13,000 rpm and the supernatant was then collected for further
analysis. Aqueous humor (AH) (200 µL), vitreous humor (VH) (500 µL) tissues were precipitated
by adding an ice cold mixture of acetonitrile & formic acid; 200 µL for AH and 500 µL for VH in
the ratio (1:1). Standard calibration curves constructed from various ocular tissues such as cornea
(20-500 ng/mL), sclera (20-500 ng/mL), AH (10-200 ng/mL), VH (10-200 ng/mL), IC (10-200
ng/mL), RC (10-200 ng/mL) were used to determine the drug concentration in the samples. All
the standard curves had a coefficient of determination r2 ≥ 0.96. The accuracy and precision of the
bio-analytical method was determined by analyzing the quality control (QC) drug samples of all
ocular matrices at three different concentration levels (50,100,200 ng/mL) each prepared in
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sextuplicate (n=6). The inter-day and intra-day variabilities in precision (% RSD) ranged between
3.97-12.6% and 4.57-9.78% in ocular tissue homogenates tested. The intra-assay and inter-assay
accuracies, expressed as the percentage difference between the measured concentration and the
nominal concentration ranged from -7.57% to 11.35% and -10.3% to 12.6% in ocular tissues
respectively. The precision and accuracies of the QC samples obtained met the requirements set
forth under bioanalytical guidance (Guidance for Industry: bioanalytical method validation in Food
and Drug Administration guidelines of September 2013) (108). Recovery of CIP was evaluated by
spiking drug in blank tissues and comparing the expected CIP concentration with standard
concentration. Recovery values were observed in AH (90.3), VH (92.9), cornea (89.7), sclera
(87.2), IC (91.5) and RC (93.3). Interference was not observed from co-eluted protein residues
with respect to CIP peaks in all the tissues. Limit of Detection (LOD) in various ocular tissues was
determined in AH (10 ng/mL), VH (10 ng/mL), cornea (20 ng/mL), sclera (20 ng/mL), RC and IC
(10 ng/mL).
3.1.10. In vivo bioavailability studies
In vivo bioavailability of CIP was determined in conscious Male New Zealand albino
rabbits weighing between (2-2.5 kg), procured from Harlan labs. All the animal studies conformed
to University of Mississippi Institutional Animal Care and Use Committee (IACUC) and
Association for research in vision and ophthalmology (ARVO) approved protocols. CIP
formulations namely marketed ophthalmic control solution, DSPE-CIP-NLCs and PEG (1K / 2K
/ 5K / 20K)-CIP-NLCs were evaluated in vivo. These topical formulations (100 µL) were instilled
as two doses (50 µL each dose) at two different time points, -30min and 0 min, to reduce precorneal loss. At the end of 2 h post application of the second drop (0 min), rabbits were euthanized
with an overdose of pentobarbital, injected through a marginal ear vein. The eyes were washed
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thoroughly with ice cold DPBS and were immediately enucleated. The intraocular tissues were
separated and stored at -80 °C until further analysis using an HPLC-UV system. All experiments
were carried out in triplicate.
3.2.

Data analysis
The steady-state flux (SSF) for transcorneal experiments was calculated by dividing the

rate of transport by the surface area. Flux was calculated using Eq. (2).
Flux(J) = (dM/dt)/A

(2)

Where, M is the cumulative amount of drug transported, and A is the surface area of the
corneal membrane (0.636cm2) exposed to the permeant (drug).
The transcorneal permeability was determined by normalizing the SSF to the donor
concentration, Cd, according to Eq. (3).
Permeability(Papp) = Flux/Cd
3.3.

(3)

Statistical analysis
One way-ANOVA coupled Post-Hoc test was employed to analyze the differences between

groups. Data obtained was considered to be statistically significant at level of (p<0.05).
3.4.

Results

3.4.1. Physicochemical characteristics of CIP containing lipid nanoparticle formulations
A detailed description of the composition of all the CIP-NLC and PEG-CIP-NLC
formulations tested, including the associated formulation codes used, have been presented in Table
3.1. Physicochemical characteristics of the various NLCs are presented in Table 3.2.
Hydrodynamic radii of all the NLC formulations did not vary significantly whereas the entrapment
efficiency values with the PEG-CIP-NLC formulations were comparatively higher than that with
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the CIP-NLCs. PEG(2K)-CIP-NLCs displayed higher entrapment efficiency – a 10% increase in
entrapment in comparison to DSPE-CIP-NLCs. Zeta potential of DSPE-CIP-NLCs decreased with
PEG derivatization from -12 to -2 mv, confirming surface charge neutralization by the PEG.
Coating of the CIP-NLCs (DSPE-CIP-NLC) with chitosan (ChCl), on the other hand, increased
the positive charge on the NLCs (Table 3.2). Physicochemical characteristics of the various NLC
formulations, post terminal moist heat sterilization are presented in Table 3.3.
Table

3.1:

Composition

of

CIP-NLCs

and

PEGylated

CIP-NLCs

(PEG-CIP-NLC)

formulations. Various PEG-CIP-NLCs were prepared using PEG conjugated phospholipids of
different carbon chain lengths and PEG molecular weights.
CIP
Formulations
(mg)

Oleic acid
(liquid
GMS (solid
lipid lipid -mg)
mg)

Phospholipid
PEGylated
Chitosan Poloxamer Tween® Glyceri Water
(mg)
Phospholipid (mg) Chloride 188 (mg) 80 (mg) n (mg) (mL)

CIP-NLCs
DMPE-CIPNLCs

30

300

150

150 (DMPE)

-

-

25

75

225

10

DPPE-CIPNLCs

30

300

150

150 (DPPE)

-

-

25

75

225

10

DSPE-CIPNLCs

30

300 mg

150

150 (DSPE)

-

-

25

75

225

10

-

25

75

225

10

-

25

75

225

10

-

25

75

225

10

-

25

75

225

10

-

25

75

225

10

PEGylated CIP-NLCs (PEG-CIP-NLCs)
PEG(1K)CIP-NLCs
PEG(2K)CIP-NLCs
PEG(5K)CIP-NLCs
PEG(10K)CIP-NLCs
PEG(20K)CIP-NLCs

150
(DSPE-PEG-1K)
150
(DSPE-PEG-2K)
150
(DSPE-PEG-5K)
150
(DSPE-PEG-10K)
150
(DSPE-PEG-20K)

30

300 mg

150

-

30

300 mg

150

-

30

300 mg

150

-

30

300 mg

150

-

30

300 mg

150

-

DMPE(2K)CIP-NLCs

30

300 mg

150

-

150
(DMPE-PEG-2K)

25

75

225

10

DPPE(2K)CIP-NLCs

30

300 mg

150

-

150
(DPPE-PEG-2K)

25

75

225

10

Chitosan coated CIP-NLCs (CIP-ChCl-NLCs)
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CIP
Formulations
(mg)

CIP-ChClNLCs

30

Oleic acid
(liquid
GMS (solid
lipid lipid -mg)
mg)
300 mg

150

Phospholipid
PEGylated
Chitosan Poloxamer Tween® Glyceri Water
(mg)
Phospholipid (mg) Chloride 188 (mg) 80 (mg) n (mg) (mL)

-

150 (DSPE)

25 mg

25

75

225

10

Table 3.2: Physicochemical characteristics of CIP-NLCs and PEGylated CIP-NLC
Formulations.

CIPNLCs

CIPChClNLCs

PEGylated CIP-NLCs

Characteris
tics
DSPECIP

PEG(1K)CIP-NLCs

PEG(2K)CIP-NLCs

PEG(5K)-CIPNLCs

DMPE(2K)CIP-NLCs

DPPE(2K)CIP-NLCs

CIPChClNLCs

-NLCs
Particle size
(nm)

190±15

165±12

180.6±13

217±18

176±4.8

184±3.6

220±16

Polydispersi
ty index
(PDI)

0.26±0.03

0.29±0.01

0.31±0.01

0.37±0.03

0.28±0.02

0.27±0.03

0.33±0.06

Zeta
potential
(mV)

12.2±1.08

-1.0±0.02

-1.8±0.08

-2.6±0.06

-2.3±0.03

-2.1±0.06

29.2±3.9

Entrapment
Efficiency
(% EE)

72.5±3.9

79.6±2.4

83.6±4.7

84.2±2.3

79.8±1.9

81.2±2

73.6±3.6

Assay (%)

CIP content was 90-95% of the theoretical value in all the formulations

Table 3.3: Effect of autoclaving on the physicochemical attributes of CIP-NLCs and PEG
-CIP-NLCs (pre and post sterilization).

Particle Size
(nm)

Polydispersity
index (PDI)

Assay

Sterilization
Stage

Sterilization Stage

Sterilization Stage

pH

Zeta potential
(mV)

Sterilizatio
n Stage

Sterilization
Stage

P
re

Pre

Formulations

Pre

Post

Pre

Post

Pre

50

Post

Post

Post

DSPECIPNLCs

14.6
±1.9
5
1.12
±0.0
1

190
±15

230±7.
5

0.26±0.03

0.35±0
.05

90.9±4.5

87.1±2.
1

5

3.6

12.2±1.08

PEG(1K
)-CIPNLCs

165
±12

169±8

0.29±0.01

0.29±0
.02

90.2±2.8

89.1±2.
6

5

4.76

-1.0±0.02

PEG(2K
)-CIPNLCs

180.
6±1
3

192±8

0.31±0.01

0.32±0
.01

90.1±3.1

88.4±3.
6

5

4.8

-1.8±0.08

1.9±
0.06

217
±18

231±9.
1

0.37±0.03

0.42±0
.02

92.6±1.8

91.9±2.
9

5

4.4

-2.6±0.06

3.4±
0.04

176
±4.8

191±7.
6

0.28±0.02

0.31±0
.04

91.4±1.1

89.4±0.
67

5

4.58

-2.3±0.03

2.9±
0.053

184
±3.6

189±8.
5

0.27±0.03

0.3±0.
02

93.2±0.9

91.8±1.
2

5

4.82

-2.1±0.06

3.3±
0.04

PEG(5K
)-CIPNLCs
DMPE(
2K)CIPNLCs
DPPE(2
K)-CIPNLCs

CIPNLCs

PEGylat
ed
CIPNLCs

3.4.2. Scanning transmission electron microscopy (STEM) studies
The STEM images of the representative samples are shown in Figure 3.1. STEM images
of CIP NLCs showed the presence of spherical as well as rod-shaped nanoparticles whereas PEGCIP-NLs appeared to be spherical in shape with a well-defined periphery. Particle sizes obtained
with TEM and DLS techniques may not be in agreement for the polydisperse formulations due to
the respective operating principles and other contributing factors. Zeta sizer measures particle size
based on intensity of scattered light whereas STEM measures it from each individual particle.
Particle size agreements may hold true in monodisperse formulations (109-111).
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Figure 3.1. STEM images of CIP loaded NLCs. A) CIP NLCs. B) PEG(2K)-CIP-NLCs.
3.4.3. Autoclave stability of CIP formulations
Physicochemical characteristics of the various NLC formulations, post terminal moist heat
sterilization are presented in Table 3.3. Following sterilization, PEGylated NLCs were able to
preserve their characteristics, whereas particle size and PDI was increased in the DSPE-CIP-NLCs
and was also accompanied by a 14% decrease in entrapment efficiency. Moreover, the DSPE-CIPNLC formulation was observed to be physically unstable (color, lipid phase separation) on steam
sterilization. Addition of various reported stabilizing agents and cloud point modifiers such as
polyvinyl pyrrolidone (PVP K30), polyvinyl alcohol (PVA Avg Mol wt 30K -70K Da), PEG 400,
PEG 1000, PEG 4000, PEG 6000 at concentrations of 0.25% and 0.5% w/v in the DSPE-CIP-NLC
formulations did not stabilize the phospholipids during the sterilization process.
Particle size and PDI of PEG-CIP-NLC formulations increased and entrapment efficiencies
decreased as a function of increasing molecular weights of PEG (2K to 20K) used in the
formulation. Moreover, PEG (20K)-CIP-NLCs appeared to be unstable during the sterilization
process, with visible supernatant oil droplets. PEGs with molecular weights of up to 10K were
observed to stabilize the DSPE-CIP-NLC formulations (Table 3.4). Formulations (represented in
tables 3 and 4) did not exhibit any statistically significant difference in physico-chemical
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characteristics, pre and post terminal moist heat sterilization except DSPE-CIP-NLCs and
PEG(20K)-CIP-NLCs, which were unstable.
Studies were then undertaken to delineate the effect of the formulation components on
autoclave stability. For this purpose, placebo formulations were used. Data on the effect of
autoclaving on the physical stability of different placebo formulations, prepared using different
lipids/phospholipids, is summarized in Table 3.5. Non-PEGylated NLCs prepared using
phospholipids (DSPE) in combination with high melting triglyceride oils such as sesame, castor
and soybean oils were stable post sterilization. NLCs prepared using a combination of the
phospholipid with a fatty-acid (oleic acid) or caprylic/capric triglyceride (Miglyol®829) or
Transcutol P were, however, unstable. These formulations were stabilized when PEGylated
phospholipid (PEG(2K)-DSPE) was used - 50% of the total DSPE used was PEGylated in these
experiments.
The effect of PEG concentration (surface packing density) on autoclave stability of
phospholipid containing DSPE-CIP-NLC formulations is presented in Table 3.6. In these
experiments the fraction of PEGylated lipid was varied from 0 to 40%, out of the total phospholipid
content in the DSPE-CIP-NLCs, using PEG grafted lipids of different molecular weights - DSPEPEG-1K/2K/5K. It was observed that DSPE-mPEG-5K stabilized the CIP-NLCs when used at a
concentration of 30% w/w of total phospholipid in the formulation. Also, DSPE-mPEG-2K had to
be used at a minimum of 40% w/w of the total phospholipid in the formulation for stabilization.
Thus, higher molecular weight PEGs required lower PEGylated lipid concentrations to impart
stability to the CIP-NLCs composition containing phospholipid and oleic acid.
Table 3.4: Effect of autoclaving on the physicochemical characteristics of PEG-CIPNLC formulations prepared with higher molecular weight PEG’s pre and post sterilization.
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Formulations

Particle Size (nm)

Polydispersity Index
(PDI)

Entrapment efficiency
(%EE)

Zeta potential
(mV)

(PEGylated
CIP-NLCs)

Sterilization Stage

Sterilization Stage

Sterilization Stage

Sterilization Stage

Pre

Post

Pre

Post

Pre

Post

Pre

Post

PEG(2K)CIP-NLCs

175.6±13

172±8

0.27±0.02

0.26±0.03

88.8±2.2

88.1±0.7

0.4±0.03

0.7±0.06

PEG(5K)CIP-NLCs

207±9

209±12

0.31±0.02

0.32±0.04

80.4±6.7

76.9±2.3

1.9±0.06

2.1±0.03

PEG(10K)CIP-NLCs

280±7

297±11.3

0.36±0.04

0.42±0.07

76.1±4.51

69.2±4.27

1.4±0.07

1.5±0.02

PEG(20K)CIP-NLCs

320±18

cracked

0.45±0.07

cracked

73.6±.9.68

cracked

0.2±0.03

cracked

Table 3.5: Physical stability of placebo NLC formulations (n=2) prepared with different
lipids (solid and / or liquid) post autoclave sterilization.
Table 3.5
Formulation

Solid lipid (mg)

Liquid lipid (mg)

Poloxamer
188 (mg)

Tween 80
(mg)

Glycerin
(mg)

Result

F-1

GMS (400)

_

5

_

_

No change

F-2

GMS, DSPE
(1:1) 9 parts
(270, 270)

Oleic acid 1 part
(60) total 9:1
(S:L)

25

75

225

Failed

F-3

Precirol (360) 9
parts

Oleic acid 1 part
(40) total 9:1 (S:L)

_

250

_

Discoloration
in one
formulation

F-4

GMS (300) 3
parts

Castor oil (100) 1
part ; 3:1 (S:L)

5

_

_

No change

F-5

Compritol (200)

Castor oil (200)

25

75

225

No change

F-6

GMS (200)

Castor oil (200)

25

75

225

No change

F-7

GMS (200)

Oleic acid (200)

25

75

225

No change

F-8

GMS (300)

Soyabean oil (300)

25

75

225

No change

F-9

GMS, DSPE
(150,150) (1:1)

Soyabean oil (300)

25

75

225

No change

F-10

GMS (300)

Sesame oil (300)

25

75

225

No change

F-11

GMS, DSPE
(150,150) (1:1)

Sesame oil (300)

25

75

225

No change
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Table 3.5
Formulation

Solid lipid (mg)

Liquid lipid (mg)

Poloxamer
188 (mg)

Tween 80
(mg)

Glycerin
(mg)

Result

F-12

GMS, DSPE
(150,150) (1:1)

Castor oil (300)

25

75

225

No change

F-13

GMS (300)

Miglyol 829 (300)

25

75

225

No change

F-14

GMS, DSPE
(150,150) (1:1)

Miglyol 829 (300)

25

75

225

Discoloration

F-15

GMS (300)

Capryol 90 (300)

25

75

225

No change

F-16

GMS, DSPE
(150,150) (1:1)

Capryol 90 (300)

25

75

225

No change

F-17

GMS (300)

Lauroglycol (300)

25

75

225

No change

F-18

GMS, DSPE
(150,150) (1:1)

Lauroglycol (300)

25

75

225

No change

F-19

GMS (300)

Lauroglycol (300)

25

75

225

No change

F-20

GMS, DSPE
(150,150) (1:1)

Lauroglycol (300)

25

75

225

No change

F-21

GMS (300)

Labrafac (300)

25

75

225

No change

F-22

GMS, DSPE
(150,150) (1:1)

Labrafac (300)

25

75

225

No change

F-23

GMS (300)

Isopropyl
Myristate (300)

25

75

225

No change

F-24

GMS, DSPE
(150,150) (1:1)

Isopropyl
Myristate (300)

25

75

225

No change

F-25

GMS (300)

Labrafil (300)

25

75

225

No change

F-26

GMS, DSPE
(150,150) (1:1)

Labrafil (300)

25

75

225

No change

F-27

GMS (300)

Transcutol (300)

25

75

225

No change

F-28

GMS, DSPE
(150,150) (1:1)

Transcutol (300)

25

75

225

Failed

Table 3.6: Effect of PEGylated to unPEGylated phospholipid ratio and PEG molecular
weight on physical stability of placebo PEG-NLC post autoclave sterilization.
% of PEGlipid

DSPE-PEG- 1K/2K/5K
lipid (mg)

DSPE Phospholipid
(mg)

Oleic acid (mg)

GMS (mg)

Result

PEG(1K)-CIP-NLCs
15

22.5

127.5

300

150

Cracked

30

45

105

300

150

Cracked

40

60

90

300

150

Cracked
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PEG(2K)-CIP-NLCs
0 (Control)

(0)

150

300

150

Cracked

10

15

135

300

150

Cracked

15

22.5

127.5

300

150

Cracked

25

37.5

112.5

300

150

Cracked

30

45

105

300

150

Droplets

35

52.5

97.5

300

150

Droplets

40

60

90

300

150

No
change

PEG(5K)-CIP-NLCs
15

22.5

127.5

300

150

Cracked

30

45

105

300

150

No
change

3.4.4. In vitro release studies
These studies combined release and transmembrane diffusion – simulating ocular CIP
penetration following topical application of the formulations. CIP flux from the DSPE-CIP-NLC
and PEG(2K)-DSPE-CIP-NLC formulations, under the test conditions employed, were similar but
the control formulation (0.3% Ophthalmic marketed control solution) showed a higher flux across
the membrane – presumably because of the elimination of the release step from the process (Figure
3.2).
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Figure 3.2: In vitro release of CIP obtained across Spectra/Por® membrane (MWCO: 3.5 KDa)
from CIP loaded PEGylated NLCs (PEG(2K)-CIP-NLCs), 0.3% w/v CIP ophthalmic Solution, and
CIP-NLCs (DSPE-CIP-NLCs) obtained using Valia-Chien cells at 34°C. (Dose: 500 µL; 1500 µg).
3.4.5. In vitro corneal permeation studies
In vitro transcorneal flux of CIP from the PEG(2K)-CIP-NLCs was almost 3-fold greater than
that achieved with control solutions. CIP flux from the PEG(2K)-CIP-NLCs was about 2-fold higher
compared to the DSPE-CIP-NLCs. Transcorneal flux of CIP from the chitosan coated NLCs (CIPChCl-NLC) was slightly better than that from the PEG(2K)-CIP-NLCs (Figure 3.3).
Carbon chain length of the phospholipid did not appear to affect transcorneal penetration
of CIP from the PEG-CIP-NLCs. The molecular weight of PEG used to derivatize the
phospholipid, however, had a significant effect on transcorneal flux of CIP (Figure 3.4). PEG (2K)CIP-NLCs (DSPE-mPEG-2000) and PEG (5K)-CIP-NLCs (DSPE-mPEG-5000) enhanced
transcorneal permeability of CIP by about 1.8-fold and 2.5-fold, respectively, when compared to
non PEGylated CIP-NLCs (DSPE-CIP-NLCs). PEG (1K)-CIP-NLCs did not exhibit a significant
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increase over the CIP-NLCs. Thus, based on the data presented in Figures 3.3 and 3.4, it can be
inferred that PEG-NLCs prepared with PEG-lipids with PEG molecular weights of 2K or greater
are preferred to enhance ocular penetration of CIP.
In another set of studies, comparative corneal permeability of PEG-CIP-NLCs prepared
with phospholipids (DSPE) grafted with higher molecular weight PEGs namely DSPE-PEG2K/5K/ 10K/20K was determined. Although, transcorneal penetration of CIP exhibited an
increasing trend with an increase in molecular weight of PEG from 2K to 10K, the difference in

*

1.40

*

1.22

1.09

1.60

1.20

0.80
0.60

0.58

1.00

0.39

Transcorneal Flux of CIP
(µg/min/cm2)

flux was not significantly different (Figure 3.5).
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Figure 3.3: Transcorneal flux of CIP obtained from CIP ophthalmic Solution, DSPE-CIP-NLCs, PEG(2K)CIP-NLCs and Chitosan Chloride coated DSPE-CIP-NLCs (CIP-ChCl-NLCs) using Valia-Chien cells at
34°C (Dose: 500 µL; 1500 µg; n=4). * symbol denotes statistical significance of PEG(2K)-CIP-NLCs and
CIP-ChCl-NLCs when compared to control and DSPE-CIP-NLCs p<0.05) .
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Figure 3.4: Transcorneal flux of CIP obtained from various topical NLC formulations tested with different molecular weights of PEG
grafted, DSPE phospholipid (PEG-1K (PEG(1K)-CIP-NLCs / 2K (PEG(2K)-CIP-NLCs / 5K (PEG(5K)-CIP-NLCs) and varied chain
lengths of PEG-2000 conjugated phospholipids (DMPE(2K)-CIP-NLCs, DPPE(DPPE(2K)-CIP-NLCs) using side-by-side diffusion
cells (PermeGear, Inc) at 34°C (Dose: 3 mL; 0.3% w/v) (n=4). * symbol denotes statistically significant difference of CIP flux from
PEG(2K)-CIP-NLCs when compared to DSPE-CIP-NLCs whereas ɸ symbol indicates statistically significant difference of CIP flux
from PEG(5K)-CIP-NLCs in comparison to all the formulations (p<0.05).
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Figure 3.5: Transcorneal flux of CIP obtained from NLC systems with higher molecular weights
of PEG’s grafted to DSPE phospholipid (2K / 5K / 10K (PEG (10K)-CIP-NLCs / 20K (PEG (20K)CIP-NLCs), using side-by-side cells at 34° C (Dose: 3 mL; 0.3% w/v; n=4).
3.4.6. In vivo bioavailability studies
Following topical application of the formulations (Table 3.1) in conscious NZW rabbits,
CIP levels in all ocular tissues tested, 2 h post dosing, were observed to be nearly 2-folds higher
with the PEG(2K)-CIP-NLCs compared to DSPE-CIP-NLCs (non-PEGylated CIP-NLCs). The
results were consistent with the in vitro observations. PEG(2K)-CIP-NLCs generated higher CIP
concentrations in all ocular tissues tested except for the cornea – where CIP-ChCl-NLCs were
observed to be slightly better (Figure 3.6).
Retinal CIP concentrations achieved with the PEG(2K)-CIP-NLCs is significantly higher
compared to all other topical formulations. PEG(5K)-CIP-NLCs was similar, if not slightly better
than the PEG(2K)-CIP-NLCs with respect to CIP levels obtained in the anterior segment tissues –
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AH, cornea and IC. CIP levels in the posterior segment or back-of-the eye tissues (retina-choroid)
was, however, below detection levels with the PEG (5K)-CIP-NLCs. The PEG(10K)-CIP-NLCs
and PEG(20K)-CIP-NLCs achieved much lower CIP concentrations in all ocular tissues tested in
comparison to the PEG(2K)-CIP-NLCs (Figure 3.6). CIP concentrations in the AH and IC,
achieved with the PEG(2K)-CIP-NLC and PEG(5K)-CIP-NLC formulations, were far greater than
the minimum inhibitory concentration (MIC90), approximately 0.5 µg/mL (112), even 2 h post
topical dosing. In contrast, commercial CIP eye drops barely maintained MIC90 levels in the AH,
IC and cornea, 2 h post dosing, while CIP levels were undetectable or below MIC in the other
ocular tissues tested.
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Figure 3.6: Ocular tissue concentrations of CIP obtained from CIP Ophthalmic Solution,
DSPE-CIP-NLCs with and without Chitosan Chloride (ChCl) and CIP loaded PEGylated NLCs
with different molecular weights of PEGs (DSPE-PEG-2K, DSPE-PEG-5K, DSPE-10K, DSPE20K) 2 h post topical application (Dose: 300 µg; 100 µL at -30 and 0 min) in a conscious rabbit
model. (AH- Aqueous humor, IC-Iris ciliary bodies and RC- Retina choroid). MIC90 of CIP is
marked as a horizontal line in the figure. Statistical analysis by One way ANOVA with post-hoc
test was performed, where symbol (*) on the ocular tissues represent statistically significant
difference of CIP concentrations from different formulations in comparison to control solution. (¥)
represents statistically significant difference of retinal concentrations obtained from PEG (2K)CIP-NLCs compared to all the formulations.
3.5.

Discussion
The focus of this project was to evaluate the effect of surface functionalization on ocular

penetration of drugs from lipid nanocarriers and formulation stability. CIP was chosen as the model
drug for preparing these formulations. Entrapment efficiency and release properties of drugs from
lipid nanocarriers are highly dependent upon interfacial area, surface charge, inner structural
organization, as well as nanoparticulate dimensions (113, 114). The size of the NPs plays a key
role in their adhesion to and interaction with the biological cells. Smaller particles can be best
internalized by receptor-mediate endocytosis uptake mechanism, while larger particles have to be
taken up by phagocytosis (115-119).
In recent years, NLCs are increasingly being considered as viable carriers in drug delivery,
but the present work introduces a new paradigm involving the concept of surface functionalization
/ modification of nanoparticles and their sterilization - stabilization characteristics. Particle size
and surface properties such as charge, morphology, hydrophilicity and surface modification with
targeting ligand functionalization are the major controlling factors for interactions with the
biological milieu (120, 121). Reports suggest that surface modification of nanoparticles by coating
with hydrophilic substances such as PEGs could further improve ocular bioavailability, mainly
due to enhanced interaction with ocular mucosal epithelium and decreased phagocytic uptake (122,
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123). Fresta et al formulated PEG-6000 coated polyalkyl-2-cyanoacrylate nanosphere
encapsulated acyclovir formulations and reported that the higher ocular bioavailability was
achieved by polyalkyl-2-cyanoacrylate colloidal carrier, but no significant difference was observed
between coated and uncoated nanospheres (124). These results may have resulted from a weak
interaction of PEG molecules with the surface of colloidal particles. In the present project we
explored the effect of nanoparticle surface modification, by adsorption of Chitosan chloride or by
firmly surface anchored PEG moieties, on ocular distribution and disposition. Also, the
characteristics of the PEG’s, optimal molecular weights and their relative concentrations needed
to achieve improved penetration, was studied.
Drug release from the nanoparticles appears to be controlled by erosion and diffusion
mechanisms through lipid matrix (125, 126). Interaction between nanoparticles and ocular
epithelial cells could be attributed to endocytosis mechanism. Based on the transcorneal
permeation data obtained, it could be said that penetration of CIP depends upon the molecular
weight of grafted PEG’s rather than it’s carbon chain length (127). The permeability was not
improved with PEG-1K and a decrease in the transmembrane flux was observed with PEG-20K,
indicating the required range of molecular weights is between 2-10K for optimal penetration
characteristics. The in vitro transcorneal permeability, an experimental set-up wherein the mucus
layer is absent, data suggests that the PEGylation not only affects penetration across the mucus
layer but also influences penetration across the corneal epithelial layers. When the PEG molecular
weight went above 10K the penetration enhancing effect was lost, which could probably be
because of the increased hydrophilicity and steric interference of the molecules.
PEGylation range within which the formulations exert the optimal penetration and steric
stabilization characteristics was further confirmed by the in vivo ocular distribution of CIP from
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the PEG-CIP-NLCs (Figure 3.6). PEGylated NLCs were able to deliver CIP, but penetration of
CIP into posterior and anterior ocular tissues decreased as a function of increasing molecular
weight of the PEG’s (128, 129). These results indicate that the lipid conjugated PEGs with
relatively higher molecular weights (greater than 5K) impart higher surface hydrophilicity onto
the nanoparticles, which limits the penetration and partition of drugs across the surface mucus
layer and epithelial membrane. The results were consistent with the in vitro observations. PEGCIP-NLCs generated higher CIP concentrations in all ocular tissues except for the cornea – in
which case ChCl-NLCs were observed to be slightly better (Figure 3.6). This, suggests that surface
modification with chitosan favors retention of the nanoparticles at the superficial ocular layers
(charge-charge interaction), whereas PEG grafting facilitates transport of the molecules across the
mucus layers as well as the cornea and other ocular tissue, consistent with earlier reports (122,
130, 131).
Tai-Lee ke et al prepared two sustained release formulations of CIP using marketed CIP
solution (0.3% w/v) with Dodecyl Maltoside as a penetration enhancer and carbopol/HPMC as
viscosity enhancers. Two hours post-topical instillation (30 µL), AH and corneal CIP
concentrations obtained with HPMC and carbopol formulation were 0.5 µg/mL and 4.2 µg/g,
respectively (132). Taha et al prepared ciprofloxacin loaded liposomes (0.3% w/v) and evaluated
AH concentration after 2 h following topical application (50 µL) in conscious rabbit model. The
AH level was increased by ~0.3-fold when compared to marketed ophthalmic solution (133). In
another study, 50 µL of CIP loaded pluronic micelles (0.3 % w/v) enhanced AH concentration of
CIP by 10%, 2 h post topical application, when compared to commercial CIP eye drops (134). In
the present study ocular bioavailability of CIP was enhanced in the anterior and posterior segment
ocular tissues, ranging from ~3-5-fold increase with PEG-CIP-NLC formulation, in comparison to
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control marketed formulation. This is significantly better than all earlier reports as well as the
currently marketed ophthalmic formulation.
All ophthalmic products need to be sterilized. Autoclavable products are preferred, from a
manufacturability point of view, over products that need aseptic processing or sterilization by
filtration. Reports suggest that phospholipids undergo acidic / basic hydrolysis (pH < 5; pH > 9)
and hence should be aseptically processed (135, 136). Our studies here demonstrate that selection
of NLC formulation components can have a significant impact on the formulation stability during
the sterilization process. Whereas long chain triglycerides components were stable, shorter chain
length fatty acids and triglyceride containing NLCs could not withstand the autoclaving step.
When a fraction of the phospholipids, in the heat unstable NLCs, were replaced with PEGylated
phospholipids, the formulations are stabilized, suggesting that PEGs are able to preserve the
supramolecular and molecular structure of colloids and protect the lipid environment. Addition of
PEG externally or other known stabilizers to the NLCs did not impart thermal stability during the
autoclave cycle. Additionally, it was observed that PEG-CIP-NLCs with PEG molecular weights
of up to 10K stabilize the NLCs during the sterilization process, whereas PEG 20K fails to do so.
Steric stabilization of liposomal formulations using PEG conjugated lipids is well documented in
the literature (137-139). PEG has also been reported to be a surface modifying agent for improving
permeability characteristics and decreasing phagocytic uptake of particulate drug carriers (52,
140). To the best of our knowledge, however, this is the first report that establishes the importance
of the molecular weight and surface density of the PEG for preparing autoclave stable NLCs with
enhanced transepithelial penetration and delivery characteristics, especially to the back-of-the eye
tissues.
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Interestingly, whereas chitosan chloride coated NLCs produced higher CIP concentrations in the
cornea and sclera, the outer tunic of the eye, this did not translate into higher CIP penetration into
the inner ocular layers. This, along with the observation that the CIP-NLCs (no surface
modification) produced low CIP levels in all ocular tissues, suggests that PEGylation within the
specified ranges improve transepithelial penetration of the CIP-NLCs into the deeper ocular
tissues.
3.6.

Conclusion
Surface functionalized NLCs appear to be a promising and effective platform for topical

ocular delivery. Surface modification strategies could improve ocular retention and intraocular
penetration of therapeutics agents; thus enhancing ocular bioavailability and distribution. In
conclusion, PEG grafted phospholipids / amphiphilic di-block copolymers with molecular weights
in the range of 2K - 5K lead to optimal ocular penetration and autoclave stability.
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CHAPTER 4
MELT CAST NONINVASIVE OCULAR INSERTS FOR POSTERIOR SEGMENT DRUG
DELIVERY
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4. Introduction
Prolonged ocular inflammation/infection could precipitate several sight threatening
disorders including, but not limited to, keratitis, conjunctivitis, iritis, uveitis, endophthalmitis,
cystoid macular edema and choroidal neovascularization (141, 142). A host of different ocular
tissues are involved in these complications, and the intricate barriers in the ocular milieu, which
are essential and exclusive to the ocular anatomy and physiology, limit the penetration of
therapeutic agents. Delivery of drugs to the posterior segment of the eye through oral/parenteral
routes is highly challenging because of the expression of blood ocular barriers. Topical
administration is promising in terms of safety and patient compliance but the delivery of
therapeutic agents to the posterior ocular tissues through this route is also an extremely difficult
task (143, 144). Although various technological advances enhanced drug delivery into the frontof-the eye, back-of-the eye delivery through the topical route needs innovative strategies to
improve pre-corneal residence and trans-ocular permeation characteristics of drug molecules (85,
145). The complex interplay between static, dynamic, efflux barriers in the eye and their
remarkable barrier functionalities, severely impedes the penetration and distribution of drug
molecules into the inner ocular tissues. Delivering the drugs to the posterior segment of the eye,
in effective concentrations, using conventional formulations like topical solutions, viscous
solutions and gels, surfactant based systems, emulsions, suspensions has not been successful so
far (83, 146). The topical solution based dosage form typically has the inherent drawback that most
of the instilled volume is eliminated from the pre-corneal area, resulting in poor ocular
bioavailability, ranging from 1-10%, of the total administered dose (147). Maurice et al calculated
that bioavailability in vitreous cavity following topical instillation of solutions range from 0.0001
to 0.0004%. Viscous mucoadhesive solutions and ophthalmic ointments prolongs the ocular
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residence time, forming drug depot on the ocular surface (148). Various colloidal nanoparticulate
systems have been designed/developed to prolong the ocular residence of drugs for delivery to the
back-of-the eye (149).
Topical formulation approaches targeting the retina through the trans-scleral pathway is
still in its infancy. Effective strategies will require candidates with ideal physicochemical
characteristics and novel strategies capable of increasing the retention and absorption on the ocular
surface. Ointments, gels and conjunctival films are dosage forms that provide close proximity to
the conjunctiva and sclera and high, localized, concentration gradient generated in the conjunctival
cul-de-sac, which favors ocular penetration, probably via the trans-conjunctiva-scleral pathway.
Solvent casting method is typically used in the preparation of ocular inserts/films. The dried
solvent cast formulations prepared using this technique can contain trace amounts of residual
solvents, which could present safety issues (147, 150). Melt-cast or melt-extrusion technique
particularly overcomes this disadvantage of solvent cast method while maintaining all the
advantages. Additionally, the technique can be easily transferred to the manufacturing floor
employing melt-extruders. The ocular inserts/films offers an attractive approach to prolong the
pre-ocular residence time as well as prolong the duration of the ocular absorption phase through
the controlled release characteristics of the films - thus increasing drug exposure to the posterior
ocular tissues.
The goal of the current research was to develop, characterize and evaluate the drug loaded
topical inserts. Indomethacin (IN), prednisolone sodium phosphate (PSP) and ciprofloxacin
hydrochloride (CIP) commonly employed in treatment of ocular inflammation and infections, and
representing a wide range of physicochemical characteristics, were chosen for investigating ocular
disposition from these topical, melt-cast films.
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4.1.

Materials and Methods

4.1.1. Chemicals
PEO [PolyOx® WSR N-10 (PEO N-10), MW: 100,000 Daltons] was kindly donated by
Dow Chemical Company (Midland, MI). IN (Indomethacin), CIP (Ciprofloxacin hydrochloride)
and PSP (Prednisolone sodium phosphate) were purchased from Sigma Aldrich (St. Louis, MO).
All other chemicals were purchased from Fisher Scientific (St. Louis, MO).
4.1.2. Animal tissues
Whole eye globes of New Zealand albino rabbits were purchased from Pel-Freez
Biologicals® (Rogers, AK), shipped overnight in Hanks Balanced Salt Solution (HBSS) over wet
ice. Corneas and whole eye globes were used on the day of receipt.
4.1.3. Animals
Male New Zealand albino rabbits (2-2.5 kg) procured from Harlan laboratories®
(Indianapolis, IN) were used for all the studies. All animal experiments conformed to the tenets of
the Association for Research in Vision and Ophthalmology statement on the Use of Animals in
Ophthalmic and Vision Research and followed the University of Mississippi Institutional Animal
Care and Use Committee approved protocols (UM protocol no: 14-022).
4.1.4. Formulations
Preparation of ocular inserts / films
Melt-cast technique was utilized for the preparation of the polymeric ocular inserts. PEO
N10, a thermoplastic polymer was selected as the matrix forming material because of its excellent
pliability and thermogelation characteristics. Physical mixtures of IN or CIP or PSP and PEO N10
were prepared by geometric dilution. Drug load in all the inserts was maintained at 10% w/w.
Polymeric films were cast using 13 mm die placed over a brass plate heated to 70°C using a hot
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plate. The physical mixture of drug and polymer was introduced into the center of the die and
compressed with the 13 mm punch to form a flat solid pre-mix. The mixture was further heated
for 2-3 min. After cooling, 4 mm x 2 x 0.2 mm rectangular inserts weighing approximately 8 mg,
providing a drug load of 0.8 mg, were cut and used for further studies.
IN control solution (IN-CS-SOL)
IN control formulation was prepared by dissolving IN in an aqueous solution containing
1% w/v Tween 80® and 29.3% w/v propylene glycol. Cationic polymer namely chitosan chloride
(Mol wt < 200kDa) (0.25% w/v) was added into the formulation and pH was adjusted to 6.8.
PSP and CIP control solutions
Marketed PSP 1% w/v ophthalmic solution (Mfg. By: Bausch and Lomb®) and CIP 0.3%
w/v ophthalmic solution (0.35 mg of CIP equivalent to 0.3 mg ciprofloxacin (base)) (Mfg. By: HiTech Pharmacal) were used as control formulations to compare with PSP and CIP inserts. CIP
control solution (0.2% w/v) prepared by dissolving CIP in phosphate buffer (pH 6.0) was used for
in vitro studies. CIP marketed formulation (0.3% w/v) served as the control for the in vivo studies.
4.1.5. Analytical procedure for in vitro samples
Analysis of drug molecules was carried out using Waters HPLC system with 600 E pump
controller, 717 plus auto sampler and 2487 UV detector. Data handling was carried out using an
Agilent 3395 integrator. IN stock solution was prepared in methanol. A 71:29.5:0.5 mixture of
methanol, water and o-phosphoric acid was used as mobile phase with Phenomenex Luna® 5
µm C18 100 Å, 250 x 4.6 mm column at a flow rate of 1 mL/min and 270 nm (42).
Analysis of CIP was carried out using mobile phase mixture of Acetonitrile and water
(50:50), pH was adjusted to 3.0 with o-phosphoric acid. Phenomenex Luna® 5 µm C18 100
Å, 250 x 4.6 mm column used at a flow rate of 1 mL/min and 299 nm (151).

72

PSP was analyzed using a mixture of 18 mM phosphate buffer: methanol (38:62) and 0.1%
w/v trimethylamine (pH 2.5) as the mobile phase. Phenomenex Luna® 5 µm C8 100 Å, 250 x 4.6
mm column was used at a flow rate of 1 mL/min and detection wavelength 218 nm. The reported
analytical method was modified and validated prior to sample analysis (152). The linearity
regression correlation coefficient in the constructed calibration curves was within the limit (≥0.99).
Percentage relative standard deviation (RSD) values for the precision were found to be less than
2%. The percentage RSD for peak area response and retention were found within the prescribed
limits. The linearity, accuracy and precision were observed to be acceptable over the working
standard ranges in the all of the analytical methods.
4.1.6. Assay and content uniformity
IN content in polymeric inserts was determined using methanol and dimethyl sulfoxide
(DMSO) 50:50 mixture as an extraction solvent. CIP and PSP was extracted from the films using
50:50 water and methanol. Content uniformity was determined from four, randomly cut, units from
a single 13 mm insert, and analyzed as described under analytical procedure using a high
performance liquid chromatography – UV (HPLC-UV) method.
4.1.7. Differential scanning calorimetry (DSC) and Fourier transform infrared (FT-IR)
Spectroscopy
DSC thermograms for pure IN or CIP or PSP, PEO N10 and the 10% w/w inserts were
collected using a Diamond Differential Scanning Calorimeter (Perkin-Elmer Life and Analytical
Sciences) (153).The samples were weighed and sealed in aluminum pans and were heated from
0oC to 270oC at a heating rate of 10oC/min under nitrogen purge (20 mL/min). Infrared spectra
(IR) for PEO N10, drug/polymer physical mixture, IN or CIP or PSP, and melt cast inserts (10%
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w/w) were obtained using a Cary 660 series FTIR (Agilent technologies) and MIRacle ATR
(Attenuated Total reflectance).
4.1.8. In vitro release and transcorneal permeability studies
In vitro release of CIP, IN and PSP from the ocular inserts was tested across standard US
100 mesh sieve in 20 mL scintillation vials. The insert was placed in the vial and the sieve was
placed over the films and 10 mL of 5% w/v RMβCD in IPBS (pH 7.4) was added as the
release/dissolution media. A stir bar was placed on the sieve and the whole assembly was placed
over a hot plate maintained at 34°C under stirring (spin bar) for 2 h. Aliquots (600 µL) were
collected at specific intervals and replaced with fresh medium. Samples taken were analyzed using
HPLC-UV.
Corneas excised from whole rabbit eyes were used for the determination of in
vitro transcorneal flux of the compounds from the various formulations. Whole eyes were shipped
overnight in HBSS, over wet ice, and were used immediately upon receipt. The corneas were
excised with some scleral portion adhering to help secure the membrane between the donor and
receptor compartments during the course of a transport study. The temperature was maintained at
34°C with the help of a circulating water bath. In vitro permeability of IN, PSP, CIP across the
corneal membrane was investigated using the Valia-Chien cells (PermeGear, Inc., Hellertown,
PA). The in vitro permeability studies were carried out for a period of 3 h. All the formulations
were tested for transcorneal permeability at equivalent doses. Four hundred microliters of IN
Control solution and IN Insert (5% w/w) (Dose: 400 µL (400 µg); 400 µg), PSP Control marketed
solution (1% w/v) and PSP Insert (10% w/w) (Dose: 80 µL (800 µg); 800 µg), CIP Control (0.2%
w/v) and CIP Insert (10% w/w) (Dose: 400 µL (800 µg); 800 µg) formulations were placed in the
donor compartment. The inserts were slightly wetted, by adding 50 µL of IPBS in the donor

74

compartment, at the start of the experiment. Aliquots were withdrawn at specific time intervals
and analyzed for CIP, PSP or IN content using HPLC-UV method.
4.1.9. Data Analysis
The transcorneal flux was obtained by dividing the rate of drug transport by the surface
area exposed to permeant and rate of transport was obtained from slope of linear regression
analysis plot between cumulative amounts of drug transported versus time. Transcorneal flux was
calculated using the equation below.
dM
Flux (J) = dt
A
Where M is cumulative amount of drug and A is the surface area of the corneal membrane
(0.636 cm2) exposed to the permeant (drug).
4.1.10. In vivo bioavailability studies
In vivo ocular bioavailability of IN, PSP and CIP was determined in conscious Male New
Zealand albino rabbits weighing between 2.0-2.5 kgs. In these studies, IN-CS-SOL, PSP and CIP
solutions (control; 100 µL) were instilled as instilled as two doses (50 µL each dose) at two
different time points, -30min and 0 min, to reduce pre-corneal loss. 10% w/w loaded IN insert
(Dose: 0.8 mg) was placed in the cul-de-sac of the rabbit eyes. Ocular bioavailability of PSP and
CIP was investigated following the instillation of 1% w/v PSP marketed topical ophthalmic
formulation (control; 100 µL: 1 mg) (Bausch & Lomb), 0.3% w/v CIP marketed solution (Control;
100 µL: 300 µg) and administration of PSP insert (Dose: 0.8 mg), CIP insert (Dose: 0.8 mg) in
conjunctival sacs of the rabbit eyes. At the end of 2 h, following topical application of the
aforementioned formulations, the rabbits were euthanized with an overdose of pentobarbital
injected through the marginal ear vein. The eyes were washed with ice cold IPBS and immediately
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enucleated and washed again. Ocular tissues were separated, weighed and preserved at -80°C until
further analysis. All experiments were carried out in triplicate.
4.1.11. Bio analytical method and samples preparation
The in vitro analytical HPLC-UV methods described above was employed for bio-sample
analysis following method validation. Protein precipitation technique was used for determining
drug concentrations in the ocular tissue homogenates. Briefly, tissues such as cornea, sclera, irisciliary (IC), retina-choroid (RC) were cut into very small pieces and added into Eppendorf® tubes.
A mixture of ice-cold acetonitrile and 0.1% w/v formic acid (1 mL) was then added to precipitate
proteins from each individual tissue. The supernatant was then collected after centrifugation for 1
h at 13,000 rpm prior to analysis. Aqueous humor (AH) (200 µL) and Vitreous humor (VH) (500
µL) were precipitated by adding an ice-cold mixture of 200 µL for AH and 500 µL for VH in the
ratio (1:1). Quantification was carried out using calibration curves constructed from respective
ocular tissues such as cornea (20-500 ng), sclera (20-500 ng), AH (10-200 ng), VH (10-200 ng),
IC (10-200 ng), RPE (10-200 ng). All the standard curves had a coefficient of determination r2 ≥
0.96. Recovery of the drugs was quantitated by spiking drug in blank AH, VH, and comparing the
expected drug concentration with standard concentration. Recovery values were determined in AH
(93.1-94.7) and VH (91.5-93.2). Interference was not observed from co-eluted protein residues
with respect to drug peaks in all the tissues.
4.1.12. Statistical analysis
All the data presented in these experiments was reported as an average of triplicate for the
same time points. One way ANOVA was carried out to test and compare treatment groups at
different levels of significance and Student t-test was used to compare differences within two
groups. A ‘p’ value less than 0.05 was considered to express statistically significant difference.
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4.2.

Results

4.2.1. Assay and content uniformity
IN / CIP / PSP content in all the inserts was approximately between 90% and 95% of the
theoretical value. The compounds were observed to be uniformly distributed within the polymeric
framework (RSD < 2.3%) and the films exhibited good pliability and tensile strength.
4.2.2. DSC and FT-IR studies
The polymeric inserts were studied for thermal characteristics and excipient compatibility
using DSC. DSC thermograms of pure PEO N10, PEO N10 film, pure drug, physical mixture and
polymeric insert are presented in Figures 4.1 and 4.2. IN (Fig. 4.1) and CIP (Fig. 4.2) exhibited an
endothermic peak at 162°C and 153°C corresponding to their melting points. PEO N10 and PEO
N10 film exhibited a melting point temperature of 68°C. The characteristic peaks of IN and CIP
were absent in the polymeric inserts indicating that there was significant reduction in crystallinity.
FTIR spectra of pure IN exhibited characteristic bands of secondary carbonyl groups
(C=O) at 1710 cm-1, (C=O amide) at 1687 cm-1, phenyl groups (C=C stretch vibration) at 1593
cm-1 and (O-H stretch vibration) at 2964 cm-1. Pure PEO revealed –CH stretching at 2880 cm-1
(Fig. 4.3). FTIR spectra of PSP showed two carbonyl stretching peaks at 1708 cm-1 and 1654 cm1

while peaks at 1596 cm-1 and 1100 cm-1 correspond to the NH and OH bending (Fig. 4.4). The

FTIR spectra of CIP showed characteristic peak at 3500 and 3450 cm-1 corresponding to OH
stretching vibration. The band at 1701 cm-1 indicated carbonyl C = O stretching, while the peak at
1617 cm-1 belongs to quinolone. The band at the 1445 cm-1 represented carbonyl group and the
peak at 1250 cm-1 suggested bending vibration of O-H group which indicated the presence of
carboxylic acid (Fig. 4.5). The FTIR spectra of physical mixtures were similar to those of
respective drugs and PEON10 individual spectra, which suggest that there was no chemical
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interaction between drug and PEON10 in physical mixtures. However, characteristic bands of the
IN (carbonyl, amide and phenyl functional groups), CIP (quinolone group) and PSP (carbonyl
group) displayed lesser degree of intensities / disappeared in the insert formulations indicating
chemical interaction between drug and the carrier occurred during the formulation processing
steps.

Figure 4.1: DSC thermograms of IN Insert, IN physical Mixture, pure IN, PEO Insert and pure
PEO.
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Figure 4.2: DSC thermograms of CIP Insert, CIP physical Mixture, pure CIP, PEO Insert and
pure PEO.

Figure 4.3: FT-IR spectra of IN Insert, IN Physical Mixture, pure IN, PEO Insert and pure PEO
N10.
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Figure 4.4: FT-IR spectra of PSP Physical Mixture, PSP Insert, pure PSP, PEO Insert and pure
PEO N10.

Figure 4.5: FT-IR spectra of CIP Physical Mixture, CIP Insert, PEO N10 Insert, pure CIP and PEO
N10.
4.2.3. In vitro release
Percentage release of IN, PSP, CIP from the polymeric films was determined to be 100.2
± 6.9, 92.7 ± 4.8 and 85.3 ± 9.4 %, respectively, at the end of 2 h (figure not presented).
4.2.4. Transcorneal permeability studies
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In vitro transcorneal flux profiles obtained from different topical insert formulations,
compared to their respective control solutions at an equivalent dose, is presented in Figure 4.6.
Transcorneal flux of IN, PSP, CIP were enhanced by ~ 3.5, ~ 3.6 and ~ 2.9-folds, respectively,
from the polymeric inserts when compared to their control formulations.

Figure 4.6: In vitro transcorneal flux obtained from different topical formulations at equivalent
doses using valia-chien cells at 34°C. Formulation tested include IN Control (0.1% w/v), IN insert
(5% w/w) (Dose: 400 µL (400 µg); 400 µg). PSP Control solution (1% w/v), PSP Insert (10%
w/w) (Dose: 80 µL (800 µg); 800 µg). CIP Control (0.2% w/v), CIP Insert (10% w/w) (Dose: 400
µL (800 µg); 800 µg). Symbolic representation on the formulation indicate the statistically
significant difference in flux compared to control.
4.2.5. In vivo bioavailability studies
Ocular tissue concentrations obtained with drug loaded polymeric inserts were evaluated
in conscious rabbit model, 2 h post topical application. IN-CS-SOL did not deliver drug into RC
but delivered into the cornea (0.9 ± 0.09 µg/g), sclera (0.4 ± 0.19 µg/g), IC (0.12 ± 0.04 µg/g) and
AH (0.15 ± 0.03 µg/g) whereas IN insert delivered drug into RC (1.08 ± 0.26 µg/g). Furthermore,
IN insert enhanced IN levels by ~10 folds (AH), ~27-folds (IC) and ~8.5-folds (cornea) when
compared to IN-CS-SOL formulation (fig.4.7.).
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Figure 4.7: In vivo IN concentrations (µg/gm of tissue) obtained from 0.1% w/v IN-CS-SOL, and
10% w/w IN Insert (Dose: 0.1 mg, 0.8 mg & 0.8 mg respectively), 2 h post topical application in
conscious rabbit model. All experiments were performed in triplicate. AH: Aqueous Humor; RC:
Retina-Choroid; IC: Iris-Ciliary. No levels were detected in VH. ND-not detectable. * Symbol
represented on ocular tissues indicate statistical significance of IN concentrations obtained from
the IN insert in comparison to control (p<0.05).
PSP control solution delivered drug into ocular tissues namely AH (0.3 ± 0.04 µg/mL), IC
(1.07 ± 0.5 µg/g), cornea (1.55 ± 0.85 µg/g) and sclera (0.77 ± 0.41 µg/g). While the PSP control
solution couldn’t deliver drug into the RC and VH, the insert - even at a lower dose compared to
the PSP control - delivered PSP into the VH (0.09 ± 0.008 µg/mL) and RC (1.28 ± 0.52 µg/g).
Moreover, the insert generated significantly greater PSP in all the other ocular tissues tested
(fig.4.8.).
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Figure 4.8: In vivo PSP concentrations (µg/gm of tissue) obtained from 10% w/w PSP Insert and
PSP control solution (1% w/v) (Dose: 0.8 mg, 1 mg respectively), 2 h post application in conscious
rabbit model. All experiments were in triplicates. AH: Aqueous Humor; RC: Retina-Choroid; IC:
Iris-Ciliary; VH: Vitreous Humor. Low levels were detectable in VH. (N.D - Not detectable).
Symbol representation on ocular tissues indicate the statistical significance of PSP concentrations
obtained from the insert formulation in comparison to control (p<0.05).
Similarly, CIP concentrations obtained with the control solution in the AH (0.51± 0.2
µg/mL), IC (0.47 ± 0.17 µg/g), cornea (0.86 ± 0.16 µg/g) and sclera (0.15 ± 0.01 µg/g) were
significantly lower than that obtained with the inserts. The control solution formulations did not
deliver CIP to the VH and RC, whereas the insert successfully delivered CIP into the VH (0.13 ±
0.05 µg/mL) and RC (0.6 ± 0.17 µg/g) (fig.4.9.).
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*

Figure 4.9: In vivo ocular tissue concentrations of CIP obtained from 0.3% w/v CIP control
solution (Dose: 100 µL; 350 µg), 10% w/w CIP Insert (Dose: 0.8 mg) in conscious rabbit model
following 2 h post topical application. AH: Aqueous Humor; RC: Retina-Choroid; IC: Iris-Ciliary;
VH: Vitreous humor. ND: Not detectable. Symbolic representation on ocular tissues indicate the
statistical significance of CIP concentrations obtained from the insert formulation in comparison
to control (p<0.05).
4.3.

Discussion
The overall objective of the current research is to develop a standard prototypical,

noninvasive, ocular drug delivery platform, effective for molecules representing a wide spectrum
of physico-chemical properties, for back-of-the eye drug delivery. The melt-cast / melt-extrusion
technology is a simple, solvent free, continuous process, for preparing unit dosage forms, which
undergo gelation upon contact with tear fluid, prolonging the release and retention on the ocular
surface. The compound to be delivered can possess a range of hydrophilicity/lipophilicity, as
demonstrated in the present project, and could be formulated at significantly higher loading.
Compounds embedded in the carrier matrix will be transformed into an amorphous state or get
entrapped as a molecular dispersion after fabrication using thermal technique. Moreover,
preservatives and solubilizers are not required, eliminating unnecessary excipients and processing
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steps. Furthermore, modified release platforms could be designed by varying the thermoplastic
polymers or molecular weights and combinations.
The solubility of CIP, a zwitterion, is greatly reduced at the pH 7.4, which is close to its
isoelectric point. This may cause CIP to crystalize when the ophthalmic solutions (formulated in
the acidic pH range) come into contact with the tear fluid. In the melt-cast inserts, for all three
drugs, absence of detectable crystalline domains in the DSC thermograms demonstrate that the
drug was completely dispersed or solubilized in the carrier polymer, at this 10% w/w drug loading.
An interaction between drug and polymer could be reflected by a change in the position of
C=O vibration and disappearance of O-H stretching in the FT-IR spectra depending on the extent
of the interaction. The FT-IR spectra of the insert formulations exhibited lower peak intensities /
were masked indicating slight interaction with the polymer PEO N10. The release studies,
however, indicated that 100% of the drug was released within 2 hours. Moreover, in vitro
transcorneal flux of the three actives from the inserts was increased by ~ 2.5 to 3.5-folds when
compared to the respective control solutions. This could be due to enhanced drug retention and
accumulation in the corneal and conjunctival epithelial layers from the transformed gel (in vitro).
Penetration of drugs through the conjunctival scleral pathway is reported in the literature
(154, 155). Ocular tissue concentrations attained with the polymeric inserts in AH, IC and cornea
was increased by ~6-8 folds in comparison to the control formulations. Cationic mucoadhesive
polymer (CS) was used at a concentration of 0.1% w/v to improve corneal penetration
characteristics and thereby intraocular bioavailability of IN from control solution. However, IC
levels obtained with IN control solution was ~27-fold lower at 1/8th dose of insert formulation. IN
control Retinal concentrations were obtained in vivo with the IN insert (1.08 ± 0.27 µg/g), PSP
insert (1.28 ± 0.52 µg/g) and CIP insert (0.60 ± 0.17 µg/g) formulations, whereas control solutions,
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couldn’t deliver drug into RC. The inserts form localized drug depots, in close proximity to the
conjunctival-scleral tissues, and thus helps drive the molecules to the retinal tissue, through the
conjunctival-scleral route. Thus, advantage of inserts, as a platform providing access to the transscleral pathway, could be exploited to overcome the physico-chemical limitations of molecules.
Additionally, feasibility of higher drug loading and use of penetration enhancers, if needed,
provides even greater flexibility to the dosage form. The melt-cast technique can be easily
translated or scaled up for manufacturing using melt-extrusion technology, which also minimizes
the exposure time to higher temperatures (2-3 minutes) allowing processing of some thermolabile
compounds also.
There have been a few reports attempting back-of-the eye delivery of therapeutic agents
through the topical route. In an earlier study, IN was loaded into nanostructured lipid carrier (NLC)
at 0.8% w/v and was evaluated in conscious rabbits, 2 h post-topical administration of 100 µL
(Dose: 800 µg). Retinal levels (0.89 ± 0.31 µg/g) were also observed with the NLC formulation
(156). In another report, an IN (0.1% w/v) ophthalmic solution made up of poloxamer® 407 (10%
w/w) enhanced AH concentrations by ∼2-fold when compared to Indocollyre® (marketed
ophthalmic solution), 2 h post-topical administration of 150 µL formulation (Dose: 150 µg) (40).
Schultz et al impregnated prednisolone into hydrogel contact lenses by placing them in diluted 5
mg/mL prednisolone suspension. These contact lenses were evaluated for posterior segment
(retina, choroid, and macula) concentrations in anesthetized rabbits following 4 h
treatments/application on days 1, 2, 5, 8 and 10. On day 11 retinal concentrations obtained were
in range of 26-166 ng/g (157). Taha et al evaluated CIP loaded liposomes (0.3% w/v) in conscious
rabbits following topical application of 50 µL formulation (Dose: 150 µg) (158). The authors
report that AH concentrations was increased by ~0.3-folds when compared to CIP marketed
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ophthalmic formulation. The polymeric noninvasive inserts developed in this study, delivered
significantly higher drug levels to all the ocular tissues tested, in comparison to the control and
other literature reports.
It is widely acknowledged that IN acts as an anti-inflammatory agent through the inhibition
of COX-2 enzyme, abundantly present in ocular tissues namely cornea, iris, ciliary body and retina
(159). Mitchell et al reported half-maximal inhibitory concentration (IC50) of IN required for
COX-2 activity in endotoxin activated J774.2 macrophages to be 0.6 µg/mL (160). MIC90 of
ciprofloxacin is reported to be 0.5 µg/mL (161). Therapeutic concentration of prednisolone
required to inhibit inflammatory mediated processes in AH (humans) is reported to be 25 ng/mL
(162). Drugs levels for optimal activity are reported in terms of solution concentrations, which
reflects the therapeutic levels needed in AH and VH tissues. Ocular tissues namely IC and RC are
in dynamic equilibrium with AH and VH, so the therapeutic levels required in AH and VH could
be interpreted to be good therapeutic response indicators in the ocular tissues. Drug levels obtained
in all the ocular tissues, post 2 h, with inserts were several folds higher than the reported minimal
concentrations, demonstrating that inserts could maintain therapeutic drug levels for prolonged
durations following topical application.
4.4.

Conclusion
In conclusion, the results from these studies suggest that the development of solvent free,

melt-cast or melt extruded ocular inserts is a highly feasible, noninvasive approach for the delivery
of a wide range of drugs, with different physico-chemical properties, to the ocular tissues. The
high localized drug loads, intimate contact with the conjunctiva, increased retention time and quick
transformation into a gel form make this efficient for delivering to the back-of-the eye tissues also.
These formulations would be marketed as unit dosage forms and do not need any preservatives or
solubilizers. Penetration enhancers may be incorporated to further increase ocular bioavailability.
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Thus, the melt-cast / melt-extruded films could shift the paradigm for drug delivery to the backof-the eye.
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CHAPTER 5
NON-INVASIVE CATIONIC COLLOIDAL NANOCARRIERS FOR OCULAR
DELIVERY OF NATAMYCIN: PREPARATION AND EVALUATION
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5. Introduction
Ocular drug delivery appears to be one of the most interesting and challenging fields for
the pharmaceutical scientist. Topical application of drugs to the eye is the most favored, safest and
popular route of administration for the treatment of various ocular disorders/complications. The
ophthalmic bioavailability of topically instilled drugs is, however, very poor due to efficient
protective mechanisms encountered in the ocular milieu (163-165). Ocular fungal infection,
namely mycotic keratitis (MK), is characterized by feathery-edged infiltrates and satellite lesions
across the cornea, which could lead to vision loss and blindness, if left untreated (166). Fungal
keratitis may attack orbit, lids, lacrimal apparatus, conjunctiva, sclera, and other ocular structures
during the progression (167). Natamycin (NT) is a macrolide polyene antifungal agent with a broad
spectrum of activity against various infectious fungi such as Fusarium, Aspergillus, and Candida
species. NT has been considered as the first line of therapy for filamentous MK (168, 169). NT
suffers from poor aqueous solubility but is effective at very low concentrations with MIC
(minimum inhibitory concentration) of less than 10 ppm. NT elicits its activity by binding to
ergosterol, a sterol unique to fungal cytoplasm (170, 171). Currently, Natacyn® (NT 5% w/v
suspension) is the only commercially available US-FDA approved ophthalmic formulation for the
treatment of MK. The frequency of administration of NT suspension is prescribed as one drop
instilled in the conjunctival sac at hourly or two hourly intervals for several days. The shortcomings
of the current therapy include high dosing frequency, long treatment duration (4–6 weeks), and
low pre-ocular residence time. The current NT therapy may not attain optimal concentration at the
site of infection, resulting in treatment failure and increased resistance (172, 173). Hence, there is
a urgent clinical need to improve patient compliance and efficiency of therapy, with reduced
frequency of administration, by designing a corneal targeted, prolonged release delivery system of
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NT. There were a few reports in the literature on ocular delivery of NT using novel approaches
(174, 175). To overcome the shortcomings associated with the marketed preparation, cationic lipid
based nanoparticles (CLBN) were developed, which could prolong pre-ocular residence and
improve mucoadhesion for efficient delivery of NT into the ocular tissues. Reports indicate that
cationic nanoparticles exhibit greater corneal affinity and interaction compared to the negatively
charged nanoparticles. The applicability of these nanoparticles as ocular delivery vehicles was
investigated in this work. The goal of the present project is to prepare NT loaded CLBN, evaluate
in vitro permeability and ocular tissue distribution in vivo, using Natacyn® 5% w/v Ophthalmic
Suspension as the control.

Figure 5.1: Chemical structure of Natamycin
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5.1.

Materials and Methods

5.1.1. Chemicals
Natamycin and di-dodecy dimethyl ammonium bromide was obtained from Sigma Aldrich
(St. Louis, MO). Glyceryl Monostearate was obtained as a gift sample from Gattefossé (Paramus,
NJ). Amicon® Ultra centrifugal filter devices with regenerated cellulose membrane (molecular
weight cut off 100 kDa), Poloxamer 188, Tween®80, high performance liquid chromatography
(HPLC) - grade solvents, and other chemicals (analytical grade) were obtained from Fisher
Scientific (Hampton, NH). Whole eyes of male albino New Zealand rabbits were obtained from
Pel-Freez Biologicals (Rogers, AR). Male albino New Zealand rabbits were procured from Harlan
Labs (Indianapolis, IN).
5.1.2. Preparation of NT loaded CLBN
NT loaded CLBN were fabricated using ultra sonication method. Solid lipids, namely
Glyceryl monostearate (GMS) and di-dodecyl dimethyl ammonium bromide (DDAB), were
melted and NT was dissolved in it to obtain the lipid phase. An aqueous phase, prepared using
surfactants such as Poloxamer 188 (0.25% w/v), Tween® 80 (0.75% w/v) and glycerin (2.25%
w/v) in bidistilled water, was heated. The hot aqueous phase was then added to the melted lipid
phase, under stirring, to form a premix (600 rpm, 1–2 min). The premix was then subjected to
emulsification at 16,000 rpm for 6 min using T 25 digital Ultra-Turrax to form a hot pre-emulsion.
The pre-emulsion obtained was subjected to ultrasonication resulting in the formation of hot
emulsion dispersion. The temperature during the entire process was maintained at 80±2°C. The
hot emulsion obtained was slowly cooled to room temperature to form NT-CLBN.
5.1.3. Analytical method for in vitro sample analysis
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Samples were analyzed for NT content using an HPLC-UV method. The system comprised
of Waters 717 plus Autosampler, Waters 2487 Dual λ Absorbance detector, Water 600 controller
pump, and Agilent 3395 Integrator. A Phenomenex Luna® C8 4.6 mm x 250 mm column was used
under isocratic elution for chromatographic analysis. The mobile phase used was mixture (70:30)
of phosphate buffer (pH 5.5) and acetonitrile.

The flow rate was set at 1 mL/min with

λmax (detection wavelength) of 304 nm during the analysis (176).
5.1.4. Physico-chemical Characterization
The hydrodynamic radius and the PDI of the NT CLBN formulation was determined by
photon correlation spectroscopy, using Zetasizer Nano ZS Zen3600 (Malvern Instruments, Inc.) at
25°C and 173° backscatter detection, in disposable clear cells. The measurements were obtained
using a helium-neon laser of 633 nm, and the particle size analysis data was evaluated using
volume distribution.
Zeta potential measurements were carried out at 25°C in disposable cells using the same
instrument. For measurement of particle size distribution and zeta potential, CLBN samples were
diluted (1:500) with water. Bi-distilled and 0.2 μM filtered water was used for these measurements,
and were performed in triplicates.
5.1.5. Assay and Entrapment Efficiency
The lipid in the NT CLBN formulation was precipitated using methanol and, drug content
in the supernatant after centrifugation (13,000 rpm for 20 min), was measured using an HPLC
system following appropriate dilution.
The percentage of NT entrapped (% EE) in CLBN was determined by measuring the
concentration of free drug in the aqueous phase of an undiluted formulation. The EE was evaluated
by an ultrafiltration technique with a 100 kDa centrifugal filter device (Amicon Ultra). An aliquot

93

(500 μL) of the corresponding formulation was added to the sample reservoir and centrifuged at
5,000 rpm for 10 min. The filtrate was analyzed for drug content using HPLC. The %EE was
calculated using Eq. (1) below. All the measurements were carried out in triplicates.
%EE=[(Wi-Wf)/Wi]×100

(1)

Where Wi =total drug content, and Wf =amount of free drug in aqueous phase.
5.1.6. In vitro release studies
In vitro release of NT from marketed ophthalmic formulation (Natacyn®) and CLBN was
evaluated by dissolution method using scintillation vials. Randomly methylated beta-cyclodextrin
(RMβCD) solution (2.5% w/v; 10 mL) prepared in isotonic phosphate buffer (pH 7.4) was used as
receiver medium during the course of the study (30 min). Twenty microliters of the control
formulation and 500 µL of CLBN was added into the medium. Aliquots (600 µL) were withdrawn
from the receiver medium at predetermined time points and analyzed using HPLC-UV system.
5.1.7. Transcorneal permeability studies
Transmembrane permeability of NT from the formulations was evaluated across isolated
rabbit cornea (Pel-Freez Biologicals®) using side-by-side diffusion cells. Three milliliters of 0.1%
w/v NT-CLBN formulation, or, 1 mL of 5% w/v Natacyn® diluted with 2 mL of phosphate buffered
saline (pH 7.4) were used as the donor formulations. Phosphate buffered saline containing 2.5%
RMβCD was used as receiver medium (3.2 mL) during the experiment (3 h). Aliquots (0.6 mL)
were withdrawn from the receiver side at predetermined time points and immediately replaced
with an equal volume of fresh RMβCD solution. Steady state flux, rate and permeability of NT
was calculated following sample analysis by HPLC-UV.
5.1.8. Biosample preparation and analysis
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In vivo sample analysis was carried out using the HPLC-UV method mentioned above
following method validation. Mixture of ice cold methanol and 0.1% formic acid (1 mL) was added
to the sample to precipitate proteins and extract the drug from individual, tissues namely cornea,
sclera, iris-ciliary (IC) and retina-choroid (RC), after cutting them into small pieces. The samples
were centrifuged for 1 h at 13,000 rpm and the supernatant was then collected for further analysis.
Aqueous humor (AH) (200 µL), vitreous humor (VH) (500 µL) tissues were precipitated by adding
an ice cold mixture of acetonitrile & formic acid; 200 µL for AH and 500 µL for VH in the ratio
(1:1). Standard calibration curves constructed from various ocular tissues such as cornea (20-500
ng/mL), sclera (20-500 ng/mL), AH (10-200 ng/mL), VH (10-200 ng/mL), IC (10-200 ng/mL),
RPE (10-200 ng/mL) were used to determine the drug concentration in the samples. All the
standard curves had a coefficient of determination r2 ≥ 0.96. Interference was not observed from
the co-eluting proteins during analysis. System configuration was as described for the in vitro
analysis.
5.1.9. In vivo bioavailability studies
In vivo bioavailability of NT was determined in conscious Male New Zealand albino
rabbits weighing between (2-2.5 kg), procured from Harlan labs. All the animal studies conformed
to University of Mississippi Institutional Animal Care and Use Committee (IACUC) approved
protocols and Association for Research in Vision and Ophthalmology (ARVO) guidelines. NT
formulations, namely marketed ophthalmic control suspension and CLBN formulation, were
evaluated in vivo at doses of 5 mg and 100 µg, respectively. These topical formulations (100 µL)
were instilled as two application (50 µL each application), at -30 min and 0 min, to reduce precorneal loss. At the end of 1 h post application of the second drop (0 min), rabbits were euthanized
with an overdose of pentobarbital, injected through a marginal ear vein. The eyes were washed
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thoroughly with ice cold DPBS and were immediately enucleated. The intraocular tissues were
separated and stored at -80 °C until further analysis using an HPLC-UV system. Ocular disposition
of NT from NT CLBN formulation was also evaluated at an additional time point - 2 h post dosing.
All experiments were carried out in triplicate.
5.1.10 Statistical analysis
One way ANOVA with Post-hoc test was carried out to analyze the difference between the
groups. Statistically significant difference was considered at a level of p<0.05.
5.2.

Results

5.2.1. Physico-chemical characteristics and in vitro release
NT content in the formulations was observed to be in the range of 92-95% of the theoretical
value. Mean hydrodynamic radius, zeta potential, polydispersity index & entrapment efficiency of
the NT-CLBN were 159.6 ±12.5; 1.24 ± 0.07 mV; 0.28 ± 0.03 and 76.4 ± 2.1 %, respectively.
Percentage release of NT from CLBN was observed to be 65 ± 1.14 in 30 minutes, whereas 94.1
± 1.93 % NT dissolved within 5 minutes from the Natacyn® ophthalmic suspension.
5.2.2. In vitro corneal permeability
Transcorneal permeability of NT was enhanced ~ 3-folds from the CLBN formulation
when compared to Natacyn® control suspension formulation. The results from these studies
suggest that cationic lipid based NT loaded nanoparticles could enhance transmembrane delivery
of the drug molecule.
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Figure 5.2: Transcorneal permeation characteristics of NT from CLBN (donor 1mg/mL)
and Natacyn® (donor 17 mg/mL) suspension across isolated rabbit cornea at 34° C (n=3).
5.2.3. In vivo bioavailability studies
The NT suspension formulation produced significantly higher corneal concentrations than
the NT CLBN. Interestingly, however, the AH NT concentration achieved with both formulations
were similar, even though there was a 50-fold dose difference. Moreover, the NT CLBN was the
only formulation that could deliver NT to the retina-choroid. Understandably, NT concentrations
at the 2 h time point was significantly lower compared to that at the end of 1h.
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Figure 5.3: Ocular tissue concentrations of NT obtained from marketed control suspension
(Dose: 100 µL; 5 mg) and NT CLBN (Dose: 100 µL; 100 µg) 1 & 2 h post topical application
in a conscious rabbit model. * symbol represents statistically significant difference of NT
control in comparison to all the formulations. $ symbol represents statistically significant
difference of NT CLBN 1h compared to NT CLBN 2h. £ symbol represents statistically
significant difference of NT CLBN 1h in comparison to all the formulations in RC.
5.3.

Discussion
Nanotechnology revolutionized the field of ocular drug delivery by overcoming the

limitations of rapid clearance and poor bioavailability into the deeper ocular tissues (177, 178).
Nanoparticles owing to their smaller particle sizes may lessen ocular shear force during blinking
elimination process, reduce discomfort and improve precorneal residence time thereby reducing
the dose and dosing frequency, making them interesting candidates for ocular delivery (179-181).
NT is amphipathic molecule with an isoelectric point of 6.5. Bulk of the NT molecule is
hydrophobic, whereas carboxyl group and mycosamine moieties are hydrophilic. NT has a
molecular weight of 665.73 g/mol and conjugated double bond structure with poor aqueous
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solubility, therefore it is formulated as a conventional ophthalmic suspension formulation (181183). Currently, NT is the only FDA-approved antifungal for the treatment of mycotic or fungal
keratitis (MK/FK). The typical frequency of dosing is one drop at hourly or 2 hourly intervals for
the first 48 hours depending on the severity of the infection and may be reduced subsequently. The
therapy is generally continued for 6 weeks or until resolution of FK (184).
MK is an infection where the drug needs to localized and maintained at the target site for
prolonged periods for management of disease condition. Polyene antibiotics with higher dose and
dosing frequency may cause corneal irritation and systemic toxicity (due to naso-pharyngeal
systemic absorption) with long term usage. Also, poor ocular bioavailability of NT from the
marketed formulation could be attributed due to its low corneal permeability (185, 186). NT
formulations with lower strength and higher penetrating ability across ocular mucosa would be
more beneficial for the anti-fungal therapy. The objective of present study is to develop cationic
lipid nanoparticulate delivery system of NT with a low payload and compare it with Natacyn in
terms of in vitro transcorneal permeability and in vivo ocular disposition.
The physico-chemical characteristics of NP namely particle size, zeta potential and
encapsulation efficiency play a crucial role in mucoadhesivity, penetration ability, and stability of
the formulation (187, 188). The particle size obtained with NT loaded nanoparticles was below
200 nm, which could cross the corneal barrier, as per previously published reports in the literature
(189-191). Also, zeta potential was slightly positive indicating that cationic lipid (DDABB)
imparted surface charge onto the nanoparticles. Release studies conducted in aqueous media (10
mL) without use of artificial membrane indicate/simulate drug release into the ocular tear fluid. It
was observed that lipid nanoparticles prolonged the NT released when compared to suspension in
the dissolution medium.
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Compared to Natacyn® control, transcorneal permeability of NT was enhanced ~3-folds
from the CLBN formulation which could be due to transcytosis/endocytosis mechanisms across
ocular epithelial layers. Also, due to the mucoadhesivity of the nanoparticles, lipid systems may
prolong the pre-ocular residence of NT, when compared to suspension formulations. The MIC90
values were found to be 1.56 and 3.12 µg/mL for A. fumigatus and C. albicans strains respectively.
Marketed suspension formulation was able to deliver ~3 and 4-fold higher concentrations to
superficial tissues such as corneal and sclera when compared to NT nanoparticles at 50-fold higher
dose 1 h post topical instillation. Lower concentrations were obtained in AH and IC tissues and
NT was undetectable in RC with marketed formulation. However, NT lipid formulations delivered
drug into RC 1 h post topical application. Cornea and sclera NT levels decreased by ~6 and 5-folds
at the end of 2h when compared to 1hr from the lipid formulation. Also, retinal levels of NT were
undetectable at the end of 2 h when compared to 1 h from the lipid formulation. NT lipid
nanoparticles maintained MIC 90 levels (aspergillus) in the cornea and RC whereas marketed
suspension formulation maintained 3, 1.7-folds over above the MIC90 levels in the cornea and
sclera at 50-fold higher dose till 1hr time point.
5.4.

Conclusion
Ultra-sonication method can be used to fabricate NT loaded cationic SLNs. The

nanoparticles exhibited optimal physico-chemical characteristics with lower hydrodynamic radius
and higher entrapment efficiency. Cationic lipid based nanoparticles of NT demonstrated better
corneal permeability characteristics and higher ocular bioavailability at lower dose when compared
to marketed suspension formulation. However, further studies are required to evaluate the clinical
efficacy of NT nanoparticles. The results from the studies suggest that NT loaded nanoparticles
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are feasible platforms for topical delivery with lower dose and dosing frequency of NT with
improved patient compliance.

101

CHAPTER 6
OCULAR DELIVERY OF RESVERATROL FOR THE TREATMENT OF DIABETIC
RETINOPATHY
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6. Introduction
Diabetic retinopathy (DR) is the most common diabetic eye disease and a leading cause of
blindness in American adults. From 2000 to 2010, the number of cases of DR increased 89%, from
4.06 million to 7.69 million, and is projected to increase to 14.6 million by 2050 (83, 84, 192).
Oxidative stress and inflammation play a critical role in the initiation and progression of DR which
could lead to progressive loss of vision and blindness if untreated (193, 194). Etiology of DR
involves multiple pathological mechanisms. Current treatment strategies of DR involve surgical
intervention, laser therapy and direct intravitreal drug administration. These extreme invasive
therapies, may cause retinal detachment, conjunctival blebs, cataracts, endophthalmitis and
increased intraocular pressure and many severe side effects (195-197). A major shortcoming of
the current pharmacological approaches is that no one candidate appears to be capable of
reversing/blocking the multifactorial pathology of DR. Multiple reports suggest that
phytochemicals, with their antioxidant and anti-inflammatory properties, may have a potential role
in the prevention and treatment of DR (198-200). Among the several other phytochemicals there
is an increasing interest in the therapeutic effects of resveratrol (RES) on the eye, particularly in
terms of intervention of DR (201-206). RES (3,5,41-trihydroxy-trans-stilbene) is a stilbenoid, a
type of natural phenol, and a phytoalexin produced naturally by several plants in response to injury
or when the plant is under attack by pathogens, such as bacteria or fungi (207). RES is present in
abundant concentrations in grape juice, peanuts, mulberries and in other plant extracts (208, 209).
The aqueous solubility of RES is reported as 300 µg/mL. RES acts as inverse agonist (cannabinoid
ligand) with high nanomolar affinities to CB1 receptors (Ki=45 nM) and micromolar affinities
towards CB2 receptors (210, 211). Inverse agonists antagonize the inflammatory properties of
endocannabinoids, specifically 2-AG and also elicit neuroprotective action by downregulating
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neurodegeneration associated processes (212). Moreover, Retina expresses CB1 and CB2
receptors, through which RES could elicit its activity (213, 214). Retinal protective effects of RES
on conditions such as oxygen and antibody-induced retinopathy, retinal neovascularization,
hyperglycemia-induced inflammation have recently been reported. Numerous reports
demonstrated neuroprotective, anti-inflammatory, anti-oxidant, antiangiogenic, anti-apoptotic and
anti-proliferative effects of RES in various pathological animal models and corresponding cell
lines (215). RES is also reported to be well tolerated with no associated toxicity and adverse effects
in humans following oral or systemic administration (216). Few reports indicated that RES did not
exert toxicity on human corneal epithelial cell lines (ATCC-CRL-11515) and human retinal
pigmented cell lines (ARPE- 19) even at higher concentrations (100 µM) (217). Furthermore, what
makes RES particularly attractive is the fact that it acts on multiple pathways involved in DR.
Minimum Inhibitory (MIC50) and Minimum Effective concentrations (MEC50) of RES,
2.5-6.5 µM (0.72-3.25 µg/mL) are to be maintained in the retina for exertion of the relevant
pharmacological activities, which is challenging in terms of delivery angle (218, 219). Lipid
nanoparticles (NPs) can prolong pre-ocular residence, impart mucoadhesivity and improve corneal
penetration when compared to conventional ocular drug delivery systems. The objective of present
study is to formulate, characterize and evaluate the corneal permeability of the lipid nanoparticles
loaded with RES.
6.1.

Materials and Methods
RES was obtained from Cayman chemical (Ann Arbor, MI). Gelucire lipids (Gelucire ®

44/14 and Gelucire® 50/13 was obtained as a gift sample from Gattefossé (Paramus, NJ).
Amicon® Ultra centrifugal filter devices with regenerated cellulose membrane (100 kDa),
Poloxamer 188, Cremophor® EL, Tween® 80, high performance liquid chromatography (HPLC) -
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grade solvents, and other chemicals (analytical grade) were obtained from Fisher Scientific
(Hampton, NH). Whole eyes of male albino New Zealand rabbits were obtained from Pel-Freez
Biologicals (Rogers, AR).
6.1.1. Saturation solubility studies
Saturation solubility of RES was studied using the standard shake-flask method. An excess
amount of RES was added to screw-capped glass vials containing different surfactants namely 1%
w/v Tween® 20, Tween® 80, Cremophor® RH 40, Cremophor® EL and Brij® 97. To achieve
uniform mixing, samples were stirred at 100 rpm for 24 h at 25°C in a reciprocating water bath
(Fisher Scientific). After 24 h, the samples were centrifuged (AccuSpin 17R®), and the supernatant
was analyzed for drug content.
6.1.2. In vitro chromatographic analysis
Chromatrographic analysis was carried out using HPLC-UV system. The system consists of
Waters 717 plus Autosampler, Waters 2487 Dual λ Absorbance detector, Waters 600 controller
pump, and Agilent 3395 Integrator. The desired chromatographic separation was achieved on a
Pheneomenex C18 column under isocratic elution using UV detection wavelength at 306 nm.
The mobile phase consisted of a mixture of methanol: 10 mM potassium dihydrogen phosphate
buffer (pH 6.8): acetonitrile (63 : 30 : 7, v/v/v) at a flow rate of 1 mL/min (220).
6.1.3. Preparation of RES loaded SLN
RES (0.7% w/v) was dissolved under stirring in melted lipid phase (Gelucire® 44/14 F-1
or Gelucire® 50/13 F-2 4% w/v). Simultaneously, an aqueous phase consisting of surfactants
namely Tween 80 (0.75% w/v), Cremophor EL (1% w/v) and glycerin (2.25% w/v) was heated to
80° C. Then, aqueous phase was added into the lipid phase, dropwise, under heat to form a coarse
emulsion. The emulsion was subjected to ultra-turrax at 16000 rpm to form pre-mix. The pre-
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emulsion was then ultra-sonicated (40% amplitude; 6 min) to form hot final emulsion. Then the
formulation was allowed to cool down to room temperature to form RES SLNs.
6.1.4. RES control formulation
RES control solution was formulated by dissolving RES (0.7% w/v) in the mixture of 2.5%
w/v Randomly methylated β-Cyclodextrin (RMβCD), 5% v/v poly (ethylene) glycol 400 and 1%
w/v Brij® 97 solution. This RES control solution was used for further studies.
6.1.5. Physico-chemical Characterization
The particle size and the PDI of the RES formulation was determined by using Zetasizer
Nano ZS Zen3600 (Malvern Instruments, Inc.) in disposable clear cells. The measurements were
obtained using a helium-neon laser of 633 nm, and the particle size analysis data was evaluated
using volume distribution. Zeta potential measurements were carried out at 25°C in disposable
cells using the same instrument. For measurement of particle size distribution and zeta potential,
RES samples were diluted (1:500) with water. Bi-distilled and 0.2 μM filtered water was used for
these measurements, and were performed in triplicates.
6.1.6. Assay and Entrapment Efficiency
The lipid in the RES formulation was precipitated using methanol and, RES content in the
supernatant after centrifugation (13,000 rpm for 20 min), was measured using an HPLC system
following appropriate dilution.
The percentage of RES entrapped (% EE) in nanoparticles was determined by measuring
the concentration of free drug in the aqueous phase of an undiluted formulation. The EE was
evaluated by an ultrafiltration technique with a 100 kDa centrifugal filter device (Amicon Ultra).
An aliquot (500 μL) of the corresponding formulation was added to the sample reservoir and

106

centrifuged at 5,000 rpm for 10 min. The filtrate was and analyzed for drug content using HPLC.
The %EE was calculated using Eq. (1) below. All the measurements were carried out in triplicates.
%EE=[(Wi-Wf)/Wi]×100
Where Wi =total drug content, and Wf =amount of free drug in aqueous phase.
6.1.7. In vitro release and transcorneal permeability studies
RES release kinetics was studied through Spectra/Por® dialysis membrane (MWCO: 3.5
kDa) at 34°C using Valia-Chien cells. Formulations, RES loaded SLNs (F-1 and F-2) and RES
control solution, were evaluated for in vitro release upto 6 h. Spectra/por® membrane is mounted
onto diffusion cells and fastened with airtight clamps. 500 µL (0.7%w/v) of formulation was added
into the donor chamber. Five milliliters of 2.5% w/v RMβCD in IPBS pH 7.4 was used as media
in the receiver chamber. Samples were taken at predetermined time points and analyzed using
HPLC-UV system.
Transcorneal permeability of RES formulations was determined across isolated rabbit
cornea using valia-chien cells (3 h). Ocular globes were shipped overnight and used for isolating
cornea. The corneal membrane was excised with some scleral portion to help secure the membrane
onto the diffusion cells and fastened between donor/receiver compartments with air tight clamps.
Five hundred microliters of 0.7% w/v RES SLNs and control solution were added into donor
chamber. Receiver chamber consisted of 2.5% w/v RMβCD in IPBS (5 mL). The samples were
taken at predetermined time points and analyzed using HPLC-UV system.
6.2.

Results

6.2.1. Physico-chemical characterization
RES SLNs exhibited lower hydrodynamic radius and higher entrapment efficiencies at a
drug load of 0.7% w/v. Particle size and PDI of two RES formulations did not show any significant
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difference. However, zeta potential and entrapment efficiency of F-2 formulation was marginally
higher when compared to F-1 formulation. The physico-chemical characteristics of SLN
formulations are presented below.
Table 6.1: Physico-chemical characteristics of RES loaded SLN formulations
Characteristics
RES-SLN F-1
RES-SLN F-2
Particle size (nm)

120 ± 12.3

131 ± 9.6

PDI

0.23 ± 0.02

0.26 ± 0.04

Zeta potential (mV)

-0.6 ± 0.01

-6.5 ± 0.05

EE (%)

87.4 ± 1.6

90.2 ± 3.8

Assay (%)

91-95

92-96

6.2.2. Saturation solubility studies
RES exhibited lower solubility in Tween 80® and predominantly higher solubility in
Cremophor EL® and Brij 97® compared to other solvents. Solubility profile of RES is presented
in figure 1.
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Figure 6.1: Saturation solubility of RES (µg/mL) obtained from various surfactants (1% w/v).
6.2.3. In vitro release and transcorneal permeability studies
Percentage release of RES SLNs was lower when compared to control formulation, due to the slow
degradation of carrier matrix. Transcorneal flux of RES, however, was increased to ~ 1.5-folds
with SLN formulation, when compared to control formulation. Transcorneal permeability of the
two RES loaded SLN formulations was not significantly different from each other under
comparison. In vitro release and transcorneal permeability of RES from the formulations is
presented in figures 6.2 and 6.3 respectively.
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Figure 6.2: In vitro release of RES from the topical ocular formulations and diffusion
across Spectra/Por® membrane (MWCO 3.5kDa) at 34°C obtained using Valia-chien cells.
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Figure 6.3: In vitro transcorneal permeability of RES from the topical ocular formulations
obtained using Valia-chien cells at 34°C.

6.3.

Discussion
The objective of the present study was to formulate and characterize the RES loaded lipid

nanoparticulate formulations. Topical, non-invasive colloidal carriers are designed to act as a drug
reservoir to modulate/tailor the drug release from the lipid core, and are endocytosed by the corneal
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epithelial cells. These carriers change the tear dynamics by decreasing tear washout/drainage and
sustain the release of drugs on the ocular surface into inner barriers (221). Lipid based nanoparticle
systems are particulates in the size range of 50-1000 nm whose matrix is made of biocompatible
solid lipids or their appropriate mixtures which are generally recognized as safe (GRAS) excipients
(222). Solid lipid nanoparticles (SLN) are considered to be among the most effective lipid-based
colloidal vehicles. They are constituted of a solid lipid matrix surrounded by a layer of surfactants
in an aqueous dispersion. Hot high-pressure homogenization, melt-emulsification, and
ultrasonication methods are generally used to fabricate the lipid nanoparticle formulations
SLNs are reported to increase the mucoadhesion and prolong pre-ocular residence when
compared to solution/suspension formulations. The particle size of nanoparticles play an important
role in the penetration across ocular mucosa (223, 224). Nanoparticles with size ranging between
50-400 nm are better tolerated than larger ones, because of their ability to penetrate across the
corneal and conjunctival barriers (225). Nanoparticles with particle size (<20 nm) are cleared by
blood and lymphatic system without achieving any ocular effect (226). The polymeric NP system
showed slow and prolonged in vitro release of the RES when compared to control formulation.
The release was slow because of the lower degradation and corrosion rate of Gelucire lipids. The
release of RES from the control formulation was higher indicating that solution formulation could
overcome the barrier resistance. Better corneal permeation characteristics for targeting intraocular
diseases such as DR is highly desirable (227). Cornea is a major and formidable barrier to the
penetration of small molecules into the inner/deeper ocular tissues. SLNs are made up of biocompatible and bio-degradable lipids which are generally recognized as safe (GRAS). In the
corneal permeation study, higher amount of RES penetrated across the excised rabbit cornea from
the Gelucire® lipid nanoparticulate formulations compared to control formulation. Transmembrane

111

flux of RES was enhanced ~1.5 folds from the lipid formulations when compared to control
solution. Reports suggest that lipid nanoparticles can cross the ocular barriers by
endocytosis/transcytosis mechanisms. The higher order of permeation was observed due to
permeation enhancement characteristics of lipid nanoparticles with their inherent mucoadhesive
properties.
6.4.

Conclusion
RES loaded SLNs are successfully prepared by ultra-sonication method. The physico-

chemical characteristics such as lower hydrodynamic radius and higher entrapment efficiencies
are achieved for lipid formulations at a higher drug load 0.7% w/v. From the in vitro study, RES
was released from the lipid nanoparticles in a slow and sustained manner than the RES control
formulation possibly due to the slow degradation of carrier matrix. Ex vivo corneal permeation
study demonstrated that the RES-loaded nanoparticles are more permeable than the control
formulation. These results suggest that RES loaded lipid systems are viable carriers for topical
ocular delivery.
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